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Abstract 
The incidence of vulvar carcinoma in younger women has increased, possibly due to augmented 
human papillomavirus (HPV) infection. Variable geographic prevalence of HPV that are 
associated with vulvar carcinoma exists. In South Africa, histological subtyping is not always 
specified and the HPV prevalence in invasive vulvar squamous cell carcinoma (iVSCC) is 
largely unknown. High HIV prevalence could also be problematic as one of the risk factors for 
HPV-dependent vulvar cancer is impaired immunological status (Saidu 2016).  The objectives 
of this study are to identify HPV subtypes in vulvar intraepithelial neoplasia (VIN) and iVSCC 
FFPE tissue using quantitative real-time polymerase chain reaction (qPCR) and to correlate 
HPV strain prevalence results with HIV status, clinicopathological features and biomarker 
expression.  
The study samples comprised of FFPE vulvar tissue from patients diagnosed with VIN and 
iVSCC at Tygerberg Academic Hospital between January 2003 and June 2018. Altogether, 72 
VIN and 68 iVSCC FFPE tissue samples were included. DNA and RNA were isolated from 
FFPE vulvar tissues and the quantity and purity were assessed using fluorometry and 
spectrophotometry, respectively. The integrity of the derived  DNA was determined through 
amplification of a 205 bp fragment of the human β-globin gene, while that of RNA was analysed 
with the RIN number and DV200 score of the Agilent 2100 Bioanalyzer. The presence of HPV 
DNA was investigated using qPCR employing primers targeting the E6/E7 gene of HPV 16, 
18, 11 and 35.  The expression of the HPV 16 and 18 E7 mRNA transcripts was examined with 
specific primers and probes using qPCR. HPV DNA detection results were correlated with 
histological diagnosis and subgroup as well as HIV status. Furthermore, tissue microarrays 
were also constructed of p16INK4a block positive immunohistochemistry samples and the 
staining pattern between the TMA and full sections were compared. 
Results show that patients between the ages of 36 to 59 years diagnosed with VIN and iVSCC 
at Tygerberg Academic Hospital between January 2003 and June 2018 were the largest 
proportion of our study population. Additionally, a significant proportion of the patients who 
were younger than 59 years, irrespective of diagnosis, were found to be HIV positive, with a 
large portion even being between 18 and 35 years old. Total DNA and RNA were extracted 
from the included FFPE vulvar tissue blocks. Overall, DNA of sufficient quality and integrity 
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was obtained as a 205 bp human β -globin gene fragment was amplified in all FFPE vulvar 
samples, suggesting that the DNA was fit for qPCR analysis.  Similarly, RNA was extracted 
from all applicable samples and was of adequate quality for use in qPCR as indicated by the 
DV200 scores, RIN numbers and the expression of GAPDH in samples converted to cDNA. 
HPV DNA was detected in 77.8 % of VIN and 66.2 % of iVSCC samples with HPV 16 being 
the most prevalent strain detected in both diagnoses. The majority of patients for which HPV 
DNA were detected were found to be co-infected with HIV. When histopathological subtypes 
were compared with HPV DNA detection, results showed that 82 % of VIN II/III (HSIL) and 
37.5 % of VIN I (LSIL) samples tested positive for HPV. Notably, a high HPV prevalence was 
also found in the keratinizing variants of the samples representative of iVSCC. Regarding 
mRNA transcript analysis, overall, the proportion of samples in which HPV 16 and HPV 18 
mRNA was expressed were slightly less than for HPV DNA detected. However, a high 
concordance was found between the two HPV detection methods, with high sensitivity and 
specificity obtained. Two tissue microarrays, one with HIV positive and the other with HIV 
negative samples, were constructed using samples that were block positive for p16INK4a IHC 
staining. When comparing the specificity and sensitivity of the p16INK4a IHC staining on full 
sections slides to that of TMA slides, results showed good agreement between scoring.  
  
In conclusion, these findings showed that VIN and iVSCC were diagnosed in women of much 
younger age in our study population compared to more developed countries. A high HIV 
prevalence was noticeable in HPV positive samples, for which HPV 16 was the most common 
subtype detected. Results also indicated that iVSCC keratinizing variants were largely 
associated with HPV in our study population which were also in contrast to what is reported. 
The findings of this study provide some insight into the prevalence of vulvar carcinoma and its 
precursor lesions, emphasizing the strong association of HPV in disease development in our 
setting. Lastly, it was also concluded that TMA’s may be utilized for ancillary testing of vulvar 
specimens, with a view of exploiting this technology for its multitude of advantages, especially 
in the context of pre-invasive HPV associated research. The search for new biomarkers, to 
predict progression from precursor lesions to invasive disease is still ongoing and inconclusive, 
therefore, further studies are needed to aid the better understanding of the aetiology and 
pathophysiology of vulvar cancer in South Africa.  
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Opsomming 
 
Die toename in die voorkoms van karsinoon van die vulva in jonger vroue kan moontlik aan 'n 
verhoogde infeksie met menslike papillomavirus (MPV) toegeskyf word. ‘MPV subtipes wat 
met  vulvêre karsinoom geassosieer word, verskil in verskeie liggings. In Suid-Afrika word die 
histologiese subtipes van die karsinoom nie altyd gespesifiseer nie en die MPV-voorkoms in 
indringende vulvar plaveiselkarsinoom (iVPK) is grootliks onbekend. Die hoë voorkoms van 
MIV kan ook problematies wees, aangesien ‘n verswakte immuuunsisteem een van die 
risikofaktore vir die ontwikkeling van MPV-afhanklike vulvêre kanker is. Die doel van hierdie 
studie is dus om, met behulp van kwantitatiewe “real-time” polimerase kettingreaksie (kPKR), 
die MPV genotipes in formalin gefikseerde, paraffienwas-ingebede vulvêre intraepiteel 
neoplastiese (VIN) en iVPK weefsel te identifiseer. Die voorkoms van MPV subtipes word met 
MIV-status, sowel as kliniese en patologiese  kenmerke asook die uitdrukking van biologiese 
merkers gekorreleer. 
 
‘n Totaal van 72 VIN en 68 iVPK gevalle wat tussen Januarie 2003 en Junie 2018 by Tygerberg 
Akademiese Hospitaal gediagnoseer was, was in die studie ingesluit. DNS en RNS was 
geekstraeër en die kwaliteit en kwantiteit daarvan was met behulp van fluorometrie en 
spektrofotometrie bepaal. Die integriteit van die DNS was deur die kPKR amplifisering van 'n 
205 bp fragment van die menslike ß-globien-geen, terwyl die van RNS met behulp van die 
RIN-nommer en die DV200-telling van die Agilent 2100 Bioanalyzer geanaliseer was. Die 
teenwoordigheid van MPV DNS was deur middel van kPKR en die gebruik van “primers” wat 
die E6 / E7-gene van MPV 16, 18, 11 en 35 teiken, ondersoek. Die uitdrukking van die MPV 
16 en 18 E7 mRNA-transkripsies is met spesifieke “primers en probes” deur middel van kPKR 
ondersoek. Die resultate van MPV tipering is met histologiese diagnose en subgroepe sowel as 
MIV-status vergelyk. Verder is weefsel “microarrays” (WMA) ook saamgestel uit monsters 
met p16INK4a blok positiewe immunohistochemie en die kleurpatroon was tussen die WMAs en 
die volledige weefsel skyfies vergelyk. 
 
Resultate toon dat die grootste deel van ons studiepopulasie uit pasiënte tussen die 
ouderdomme van 36 tot 59 jaar wat gediagnoseer was met VIN en iVPK in die Tygerberg 
Akademiese Hospitaal tussen Januarie 2003 en Junie 2018, bestaan het. Boonop is daar gevind 
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dat 'n beduidende deel van die pasiënte jonger as 59 jaar oud en MIV-positief was, ongeag van 
die diagnose, met 'n groot gedeelte selfs tussen 18 en 35 jaar oud. Oor die algemeen was DNS 
van voldoende gehalte en integriteit verkry en die menslike ß-globiengeenfragment is in alle 
vulvêre monsters geamplifiseer, wat daarop dui dat die DNS geskik was vir kPKR-ontleding. 
Net so was RNS uit alle geskikte monsters geekstraeër en dit was van voldoende gehalte vir 
die gebruik in kPKR, soos aangedui deur die DV200-tellings, RIN-getalle en die uitdrukking 
van GAPDH in monsters wat omgeskakel was na komplimentêre DNS. MPV-DNS is in 77,8 
% van die VIN en 66,2 % van die iVPK-monsters opgespoor, met MPV 16 as die mees 
algemene MPV tipe wat by albei diagnose gevind was. Die meerderheid van die pasiënte 
waarvoor MPV-DNA gevind was, was ook met MIV geïnfekteer. Toe histopatologiese 
subtipes met die MPV DNA bevindings vergelyk was, was daar getoon dat 82 % van die VIN 
II / III (HSIL) en 37,5 % van die VIN I (LSIL) monsters positief vir MPV getoets het. 'n 
Verhoogde voorkoms van MPV was ook in die keratiniserende variante van die iVPK monsters 
gevind. Wat die analise van mRNA-transkripsie betref, was die proporsie van monsters waarin 
MPV 16 en MPV 18 mRNA uitgedruk was, effens minder as vir die waar MPV-DNA gevind 
was. Daar was egter 'n hoë ooreenkoms tussen die twee MPV-ontledingsmetodes gevind en 'n 
hoë sensitiwiteit en spesifisiteit was ook getoon. Twee WMA’s, een met MIV-positief en die 
ander met MIV-negatiewe monsters, was saamgestel uit monsters wat blok-positief vir p16INK4a 
IHC-kleuring was. Die spesifisiteit en sensitiwiteit van die p16INK4a IHC-kleuring op volledige 
skyfies en die TMA-skyfies was vergelyk en ‘n goeie ooreenkoms tussen die uitkoms van IHC 
kleuringspatroon was getoon. 
 
Ten slotte, hierdie bevindings het getoon dat VIN en iVPK by baie jonger vroue in ons 
studiepopulasie gediagnoseer was, in vergelyking met meer ontwikkelde lande. 'n Hoë 
voorkoms van MIV was opvallend in MPV-positiewe monsters, met MPV 16 die algemeenste 
subtipe wat  gevind was. Resultate het ook aangedui dat die keratiniserende iVPK variante 
grootliks met MPV in ons studiepopulasie geassosieer was, wat ook teenstrydig is met wat 
gerapporteer word. Die bevindings van hierdie studie bied 'n mate van insig in die voorkoms 
van vulvêre karsinoom en hul voorloper letsels , wat die sterk assosiaise tussen MPV en die 
ontwikkeling van die kanker in ons omgeweing uitbeeld. Laastens is die gevolgtrekking 
gemaak dat WMA's gebruik kan word vir aanvullende toetsing van vulvêre monsters, met die 
doel om die tegnologie se talle voordele te benut, veral in die konteks van pre-infiltrerende 
MPV-geassosieerde navorsing. Die identifisering van nuwe biomerkes, wat die vordering 
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vanaf voorloper letsels na infiltrerende siekte is steeds deurlopend en onbeslis, daarom word 
verdere navorsing egter benodig om die etiologie en patofisiologie van vulvêre kanker in Suid-
Afrika beter te verstaan. 
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Chapter 1   
The role of human papilloma virus in the development of vulvar 
intraepithelial neoplasia and invasive vulvar squamous cell 
carcinoma. 
 
 
1.1 Background 
Vulvar cancer incidence has been increasing in the last few decades while the age of patients 
at diagnosis has decreased (De Vuyst et al., 2009; De Sanjosé et al., 2013; Preti, Scurry and 
Marchitelli, 2014; Trietsch et al., 2015; Bradbury et al., 2016; Saidu, 2016). This may be linked 
to an increase in human papillomavirus (HPV) infection (Saidu, 2016), which is one of the risk 
factors for vulvar pre-cancer and cancer development. A recent study suggests the average age 
of women with vulvar carcinoma in South Africa to be 52.5 years (Butt and Botha, 2017). A 
significant difference in age groups thus exists as 64 and 70 years is described for women, 
diagnosed with vulvar carcinoma, in international literature from high-income countries such 
as the United States of America, Australia and the Netherlands (Ramanah et al., 2012; Tan et 
al., 2012 as cited in Butt and Botha, 2017). A recent study shows that the prevalence of HPV 
in women from Cape Town aged 16 to 22 years is 68.2 % (Mbulawa, Schalkwyk, Hu, Meiring, 
Barnabas, Dabee, Jaspan, Kriek, Jaumdally, Muller, Bekker, Lewis, Dietrich, Gray, Passmore 
& Williamson, 2018). According to this study, cervical samples of Capetonian women are more 
likely to have multiple HPV infections compared to that of women residing in the Gauteng 
region (Mbulawa et al., 2018). Globally, human papillomavirus (HPV) was the cause of 640 
000 out of 2.2 million (approximately 29 %) new cancer cases in 2012, making HPV infection 
one of the major causes of oncoviral related cancers (Plummer, de Martel, Vignat, Ferlay, Bray 
& Franceschi, 2016; Serrano, De Sanjosè, Tous, Quiros, Muñoz, Bosch & Alemany, 2015). 
HPV infection is linked to 30 % to 43 % of invasive vulvar carcinoma cases and approximately 
85 % of high-grade vulvar intraepithelial neoplasia (VIN) cases (Serrano et al., 2015). 
Furthermore, 25,6 million people in Sub-Saharan Africa and 7.7 million people in South Africa 
were living with HIV in 2018 (Global UNAIDS report, 2019). High HIV prevalence could be 
problematic as one of the risk factors for HPV dependent vulvar cancer is impaired 
immunological status (Saidu, 2016). HPV-related cancer statistics in South Africa is lacking, 
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though the last data published by the National Cancer Registry was in 2014, indicated an 
incidence of 343 histologically diagnosed vulvar cancer cases. However, this total has 
remained unchanged for the years 2013 and 2014, suggesting a lack of updated statistics for 
this cancer type. Nevertheless, a slight increase in vulva diagnosis has been seen in South 
Africa as 323 cases were diagnosed in 2012 according to the National cancer Registry (Herbst, 
2016). Additionally, the latest HPV summary report for South Africa, updated and released in 
2019, reports vulvar carcinoma incidence of 22 cases between 2008 to 2012 for the Eastern 
Cape only and still have no available data on HPV prevalence among vulvar cancer cases 
elsewhere in South Africa (Bruni et al., 2019). There is clearly a void in knowledge regarding 
the prevalence of vulvar cancer in South Africa. Therefore, an increase in studies pertaining to 
vulvar cancer and other low incidence anogenital malignancies are much needed in Sub-
Saharan Africa. 
 
In the text that follows, a literature review is presented. An overview of the epidemiology of 
HPV and vulvar carcinoma is provided followed by the clinical and histological features of 
vulvar carcinoma. Next, a brief insight is given into the classification system used for vulvar 
neoplasia and carcinoma diagnosis followed by a summary of the treatment, prevention and 
management of HPV and vulvar malignancies. A detailed explanation of the molecular 
mechanism of HPV-related vulvar carcinoma is then provided, followed by the influence of 
HIV, a known risk factor for HPV infection, on this disease. As the source material used in this 
study is formalin-fixed paraffin embedded (FFPE) vulvar tissue, insight into the utility of 
FFPE-derived nucleic acids in sensitive molecular applications such as qPCR is provided. 
Lastly, a short information piece on the use of biomarkers for HPV-related cancers such as 
vulvar carcinomas as well as the use of tissue microarray is given.  
 
1.2 Epidemiology of HPV and vulvar carcinoma 
According to a worldwide meta-analysis study, HPV prevalence has increased in less 
developed countries (15.5 %) compared to developed countries (10.0 %) with the highest HPV 
incidence occurring in women younger than 25 years (De Sanjosé et al., 2007). HPV 
prevalence was found to be the highest (22.1 %) in African women with normal cytology while 
a single study included in this meta-analysis estimated the HPV occurrence in South African 
women to be 15.5 % (De Sanjosé et al., 2007).  A significant geographical difference in HPV 
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prevalence rates was observed by Reade, Eiriksson and Mackay, 2014, making the 
identification of prevalent HPV strains in individual settings a relevant and important research 
aspect. HPV prevalence therefore differs from country to country with another study referring 
to Africa having the highest HPV prevalence of 32 % while that of Asia was a mere 6 % 
(Hinten, Meeuwis, van Rossum & de Hullu, 2012). 
 
Squamous cell carcinoma (SCC) of the vulva is preceded by the precursor lesion vulvar 
intraepithelial neoplasia (VIN). VIN can either develop via an HPV associated pathway 
resulting in usual VIN (uVIN) or an HPV independent pathway leading to differentiated VIN 
(dVIN) (Alkatout, Schubert, Garbrecht, Weigel, Jonat, Mundhenke & Günther, 2015; Hoang, 
Park, Soslow & Murali, 2016; Léonard, Kridelka, Delbecque, Goffin, Demoulin, Doyen & 
Delvenne, 2014; Saidu, 2016). Differentiated VIN mainly occurs in older, post-menopausal 
women (55 to 85 years) and shows a low rate of HPV infection (Alkatout et al., 2015; Bradbury 
et al., 2016). Chronic vulvar dermatosis such as Lichen sclerosis has been described as a 
predisposing risk factor for the development of dVIN as it causes severe pruritus which may 
lead to squamous cell hyperplasia, progression to atypia, development of VIN and eventually 
invasive vulvar carcinoma  (Alkatout et al., 2015; Bradbury et al., 2016; De Sanjosé et al., 
2013).  
 
Unlike dVIN, uVIN usually affects younger women (35 to 65 years old) and is associated with 
smoking and impaired immunological status (Saidu, 2016). Other predisposing risk factors 
include previous sexual transmitted diseases and low economic status (Alkatout et al., 2015).  
Although spontaneous regression of disease does occur in some cases, women with untreated 
u-VIN have an increased risk for disease progression, as approximately 80 % of women with 
untreated VIN III (high grade lesion) develop invasive carcinoma  (Canavan and Cohen, 2002; 
Alkatout et al., 2015; Hoang et al., 2016).  Approximately 18 % to 52 % of women diagnosed 
with u-VIN also presents with squamous dysplasia in other anogenital sites (Hoang et al., 
2016).  
 
Several types of vulvar cancer such as basal cell carcinoma, adenocarcinoma, sarcoma and 
melanoma exist but squamous cell carcinoma (SCC) is the most common type of vulvar cancer 
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and accounts for 90 % to 95 % of vulvar malignancies (Alkatout et al., 2015; Léonard et al., 
2014; De Sanjosé et al., 2013). Histological subtypes of vulvar squamous cell carcinoma 
(VSSC) include basaloid and warty SCC which are normally associated with HPV infection 
(Knopp et al., 2009; Preti, Sccurry and Marchitelli, 2014). Other histological subtypes include 
verrucoid,  keratinizing and non-keratinizing SCC and are often unrelated to HPV infection 
(Knopp et al.,2009; Preti, Sccurry and Marchitelli, 2014).  
 
1.3 Clinical and histological features of vulvar carcinoma 
Symptoms of vulvar carcinoma include a visible lump in or around the vulva area as well as a 
long history of pruritus (itchy skin), pain, discharge and bleeding (Alkatout et al., 2015; 
Bradbury et al., 2016).  As no current screening method for vulvar cancer exists, VIN is usually 
diagnosed after symptoms have already occurred (Preti, Sccurry and Marchitelli, 2014). During 
clinical evaluation the site, size, shape, amount and colour of the lesion is recorded and will 
indicate if further testing is necessary (Preti, Sccurry and Marchitelli, 2014).  
 
1.3.1. uVIN 
Usual VIN (uVIN) is often defined as unifocal or multifocal with elevated lesions on the 
opening of the vaginal canal and labia minora and normal surrounding mucosa (Preti, Sccurry 
and Marchitelli, 2014).  Positive diagnosis of VIN in association with HPV infection does not 
always lead to invasive vulvar carcinoma and may persist, progress or resolve spontaneously 
without treatment (Saidu, 2016).  However, although data is limited, it was found that HIV-
positive women with a HPV co-infection plus multifocal and multicentric VIN lesions have an 
increased risk of recurrent disease and development of invasive vulvar carcinoma (Bradbury et 
al., 2016).  Studies done on HPV strain prevalence in cervical cancer cases also showed the 
tendency of HIV positive patients to be infected with multiple high-risk HPV types, which 
could be linked to the rapid disease progression (Williamson, 2015). As HPV is strongly 
associated with the development of uVIN, identifying the prevalent HPV strains present in HIV 
positive and negative patients could be extremely valuable for prognosis, preventative 
treatment and for the evaluation of HPV vaccine efficiency.   
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During the development of uVIN, atypical basaloid cells start to proliferate in the basal layer 
and continue to do so throughout the full thickness of the squamous epithelium until maturation 
into squamous cells near the surface of the epithelium (Preti, Sccurry and Marchitelli, 2014). 
Atypical mitoses and apoptotic bodies are common features in atypical basaloid cell 
proliferation while koilocytosis (HPV-induced cellular changes leading to structurally altered 
squamous epithelial cells) only becomes evident after the development of mature squamous 
cells (Preti, Sccurry and Marchitelli, 2014). As previously mentioned, HPV associated SCC 
arises from uVIN lesions and can be histologically described as basaloid or warty, however an 
intermediate form, warty-basaloid VIN is also common (De Sanjosé et al., 2013; Preti, Sccurry 
and Marchitelli, 2014). Warty VIN is characterized by the presence of HPV-associated 
cytopathogenic changes such as koilocytes while basaloid VIN contains atypical basaloid cells 
(Preti, Sccurry and Marchitelli, 2014).  
 
1.3.2. dVIN 
Clinical symptoms of dVIN include poorly defined white or pink plaque lesions in combination 
with a long history of itching, soreness, pain, burning, bleeding, dryness and other common 
symptoms of lichen sclerosis or lichen planus (Preti, Sccurry and Marchitelli, 2014).  These 
lesions are often treatment-resistant which is another indication of dVIN and do not commonly 
affect surrounding areas such as the vagina, cervix and anus (Preti, Sccurry and Marchitelli, 
2014).  A diagnosis of dVIN is challenging to make as it has subtle histological criteria to 
distinguish it from lichen sclerosis (Preti, Sccurry and Marchitelli, 2014). dVIN is 
histologically identified through basal nuclear atypia and premature maturation of cells above 
the basal layer (Preti, Sccurry and Marchitelli, 2014).  
 
 
1.4. Vulvar pre-cancer lesion and carcinoma classification 
A variety of pathological classification systems for vulvar pre-cancer lesions and vulvar 
carcinoma exists such as the American Joint Committee on Cancer TNM as well as the 
International Federation of Gynecology and Obstetrics (FIGO) staging systems (Alkatout et 
al., 2015). These two systems classify vulvar carcinoma based on the size of the tumour, 
whether lymph nodes are affected as well as metastasis of the tumour to distant sites (Alkatout 
et al., 2015). The International Society for the Study of Vulvovaginal Disease (ISSVD) began 
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to use the term VIN in 1986 which was divided into three grades according to the extent of the 
dysplasia throughout the epithelial thickness (Hoang et al., 2016). VIN I referred to cases where 
dysplasia occurred throughout the lower one-third of the epithelial thickness, VIN II was 
diagnosed where two-thirds of the epithelial thickness was affected and VIN III was diagnosed 
when more than two-thirds of the epithelial thickness was affected (Hoang et al., 2016). The 
ISSVD also introduced another category termed VIN III differentiated type (Hoang et al., 
2016). However, it later became evident that this classification system was not sufficient as the 
majority of VIN I cases were associated with low-risk HPV types and very seldom progressed 
to vulvar cancer while VIN II and III was linked to high-risk HPV and had an increased risk 
for progression to iVSCC (Hoang et al., 2016). The classification system was therefore 
changed in 2004 referring to all high-grade lesions as VIN only while the VIN I classification 
was removed and these lesions now referred to as a wart or HPV infection (Preti, Sccurry and 
Marchitelli, 2014; Hoang et al., 2016).  The ISSVD then further changed the classification to 
usual type VIN (uVIN) which includes lesions previously diagnosed as VIN II and VIN III, 
differentiated type VIN (dVIN) and unclassified VIN (VIN, not otherwise specified (NOS)) 
(Preti, Sccurry and Marchitelli, 2014; Hoang et al., 2016).  Due to the small amount of VIN I 
cases that is linked to high-risk HPV types, the World Health Organization (WHO) continues 
to classify uVIN into three grades (VIN I – III), where VIN I would be equivalent to low grade 
squamous intraepithelial lesion (LSIL) while VIN II and III would be regarded as high-grade 
squamous intraepithelial lesions (HSIL) according to the classification used by the Lower 
Anogenital Squamous Terminology (LAST) guidelines published in 2012 (Preti, Sccurry and 
Marchitelli, 2014).  The classification of vulvar lesions has since been standardized as the 
“squamous intraepithelial lesion (SIL)” terminology proposed in this document by the College 
of American Pathologist (CAP) and American Society for Colposcopy and Cervical Pathology 
(ASCCP) was widely accepted by a variety of committees (Hoang et al., 2016). The WHO and 
ISSVD also later accepted the SIL terminology but also includes dVIN as a separate category 
(Hoang et al., 2016).  
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1.5. Treatment, prevention and management of HPV, vulvar intraepithelial 
neoplasia and invasive vulvar carcinoma 
No specific HPV test is available at Tygerberg Academic Hospital and an HPV positive 
diagnosis is mainly reliant on the observation of histological HPV changes such as koilocytosis 
(Butt and Botha, 2017). Recently, the option to request p16INK4a immunohistochemistry (IHC) 
staining for some cases, a known surrogate marker for HPV-related morphological changes, 
has been implemented at Tygerberg Academic Hospital (Personal communication with Dr R. 
Razack, pathologist).  
 
A variety of PCR-based HPV DNA testing methods have been developed such as the HPV 
linear array kit (Roche), Cobas® HPV test (Roche) and the HPV Direct Flow Chip kit (Master 
Diagnostica). Other approaches available for the testing of the presence of HPV are IHC as 
well as In situ hybridization (ISH) (Molijn et al., 2005). However, HPV testing for vulvar 
carcinoma patients may be redundant, as symptoms have often already occurred when VIN is 
diagnosed and a biopsy or surgery is the next step of action. Treatment methods available for 
vulvar carcinoma are invasive as radical surgery, sometimes in combination with pre- or 
postsurgical radiotherapy or chemotherapy is often the mainstay of treatment (Butt and Botha, 
2017; Knopp, et al., 2009; Wills and Obermair, 2013).  At Tygerberg Academic Hospital, 
surgery was the primary treatment for 62.7 % of vulvar carcinoma patients between January 
2001 and December 2014, with 40.7 % of these patients undergoing adjuvant therapy, such as 
radiotherapy, post-surgery (Butt & Botha, 2017). The type of surgery performed is dependent 
on the size and extent of the invasion of the lesion (Herbst, 2016). A wide local excision is 
commonly performed in early-stage disease cases where the lesion, as well as a margin of 
surrounding healthy tissue, is excised (Alkatout et al., 2015; Herbst, 2016). Other types of 
surgery include partial vulvectomy, radical vulvectomy with or without the removal of adjacent 
infected organs, reconstructive surgery and removal of nearby lymph nodes (Alkatout et al., 
2015; Herbst, 2016). These harsh treatment methods can lead to severe physical, sexual and 
psychological dysfunction (Wills & Obermair, 2013). Post-surgical complications such as 
lymphedema, hematoma, wound infection, breakdown, cellulitis and hernia formation may also 
occur (Wills & Obermair, 2013). Several techniques have been developed to decrease these 
complications. For example,  sentinel lymph node biopsy which may allow fewer lymph nodes 
to be removed by identifying the lymph node where the cancer is most likely to spread to first 
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(Herbst, 2016). At some institutions wound healing disorders are minimized by replacing the 
traditional en bloc resection with the triple incision (Alkatout et al., 2015).  
 
Despite differences in aetiopathogenesis and cellular mechanism of HPV dependent and 
independent iVSCC, treatment options for both iVSCC types remain the same. However, 
current research is evolving around developing targeted agents and differing treatment 
strategies for iVSCC (Reade, Eiriksson & Mackay, 2014). Targeted treatment works similarly 
to chemotherapy but is specially produced to target cancer cells with a specific type of 
alteration. For example, as an increase in epidermal growth factor receptor (EGFR) was 
observed in vulvar squamous cell carcinoma, the use of anti-EGFR tyrosine kinase inhibitor 
drugs such as erlotinib and gefitinib have been investigated as a form of targeted treatment 
(Horowitz, Olawaiye, Borger, Growdon, Krasner, Matulonis, Liu, Lee, Brard & Dizon, 2012; 
Inrhaoun, Elghissassi, Gutierrez, Brain & Errihani, 2012; Olawaiye, Lee, Krasner & Horowitz, 
2007). Increase in EGFR gene copy numbers was however associated with the absence of high-
risk HPV types indicating that this form of therapy may not be beneficial for vulvar cancer 
caused by high-risk HPV (Horowitz et al., 2012).  
 
A variety of HPV vaccines such as Gardasil®, Cervarix® and Gardasil 9® have been 
developed to protect against numerous HPV types including HPV 16, 18, 6, 11, 31, 33, 45, 52 
and 58 (Buchanan, Graybill and Pierce, 2016). These HPV vaccines have been widely used in 
developed countries and are reported to prevent  up to 90 % of HPV-related anogenital cancers 
(Buchanan, Graybill and Pierce, 2016). Two HPV vaccines are currently registered in South 
Africa,  CervarixTM, which prevents infection with HR-HPV types 16 and 18; as well as 
GardasilTM containing antigens for HPV 16, 18, 11 and 6 (Botha & Dochez, 2012). However, 
the determination of prevalent HPV types in different settings is needed to confirm whether 
current HPV vaccines protect against those specific HPV types. A recent case report study also 
suggested the use of HPV vaccines as a therapeutic agent as the administration of Gardasil® 
in a recurrent vulva carcinoma patient prevented disease relapse (Gustafson, Gade & Blaakær, 
2014).  The Vaccine and Cervical Cancer Screen project (VACCS) were recently completed in 
South Africa targeting primary school girls in grade 4 to 7 (>9 years old) in the Gauteng and 
Western Cape provinces (Snyman et al., 2015). Findings of the project was that vaccination 
programmes can be successfully implemented in primary schools in South Africa and that 
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appropriate age groups for HPV screening was reached (Botha and Dochez, 2012; Snyman et 
al., 2015).  
 
1.6. Molecular mechanism of HPV related vulvar carcinoma 
HPV have a specific affinity for epithelium while some HPV types may also have a cutaneous 
or a mucosal specificity making the anatomical site susceptible to infection by a specific virus 
type (Thomas, Pim & Banks, 1999). The HPV genome is a small circular double-stranded DNA 
molecule consisting of 6 early genes (namely E1, E2, E4, E5 E6 and E7) and two late genes, 
called L1 and L2 (Narisawa-Saito & Kiyono, 2007). The HPV subtype  is determined by the 
E6, E7 and L1 gene regions as more than 10 % variation in nucleotide sequence in these regions 
are required for the HPV strain to be defined as a different HPV type (Burk, Harari & Chen, 
2013; Ishiji, 2000; Pande, Jain, Prusty, Bhambhani, Gupta, Sharma, Batra & Das, 2008). More 
than 100 different HPV types have been identified of which approximately 40 of these 
genotypes are known to infect the genital mucosa (Narisawa-Saito & Kiyono, 2007; Shikova, 
Todorova, Ganchev & Kouseva-Dragneva, 2009; Zhang, Zhang & Zhang, 2018; Zhu, Wang, 
Mao, Zhang & Ma, 2019). Infection with the majority of the HPV subtypes, such as HPV 6 
and HPV 11, will lead to non-cancerous proliferative lesions or warts and is therefore named 
low-risk HPV types. On the other hand,  HPV subtypes such as HPV 16, HPV 18 and HPV 35  
are categorised as high-risk types, as they are known to be oncogenic and may result in pre-
malignant or malignant lacerations (Knopp et al., 2009; Zhu et al., 2019). A recent third HPV 
subtype classification group namely “possibly high-risk” is used to classify HPV subtypes 
which may have the ability to be cancer-causing such as HPV 26 and HPV 30 (Zhu et al., 
2019).  
 
1.6.1 Mechanism of HPV associated malignancy 
The initial HPV infection is regulated by receptors of HPV, known as Heparan sulfate 
proteoglycans (HSPG) as well as α6-integrin and laminin-5 facilitates ensure sufficient initial 
HPV infection (Senapati, Senapati & Dwibedi, 2016). HPV then gains entry into the exposed 
basal cells of the epithelial mucosa after tissue trauma such as micro-tearing has occurred, a 
process which may take up to 12 hours (Senapati et al., 2016; Tong, Zheng, Zhao, Xing, Li, 
Lin, Zhang & Jin, 2016).  HPV DNA integration begins at integration “hotspots”, which are 
sites throughout the genome which are not repaired after DNA damage induced by factors such 
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as oxidative stress as well as the E1, E6 and E7 HPV proteins (Senapati et al., 2016). As the 
cell attempt to repair itself using the DNA damage response pathway, viral particles known as 
episomal HPV, takes advantage of this pathway to replicate (reviewed in Senapati, Senapati 
and Dwibedi, 2016). This leads to overexpression of viral E6 and E7 early genes causing the 
production of E6 and E7 oncoproteins (Tong et al., 2016). HPV E6 gene products degrade p53, 
a human tumour suppressor protein, via the ubiquitin pathway (Figure 1.1) (Bernard, Robinson, 
Nominé, Masson, Charbonnier, Ramirez-Ramos, Deryckere, Travé & Orfanoudakis, 2011; 
Narisawa-Saito & Kiyono, 2007; Thomas et al., 1999). E6 oncoproteins interact with E6-AP, 
an E3 ubiquitin-ligase, which modifies the affinity of E6-AP for p53 (Figure 1.1) (Bernard et 
al., 2011; Narisawa-Saito & Kiyono, 2007; Thomas et al., 1999). Subsequent binding of E6-
AP to p53 then leads to ubiquitination of p53 which is then degraded by the 26 S proteasome 
complex (Figure 1.1) (Bernard et al., 2011; Narisawa-Saito & Kiyono, 2007; Thomas et al., 
1999).  p53 is responsible for the regulation of the cell cycle as this protein is expressed in 
reponse to DNA damage or  initiation of unscheduled DNA replication (Gaëlle et al., 2007). 
Degradation of p53 thus results in loss of cell cycle arrest, survival of damaged cells and 
suppression of apoptosis which leads to uncontrolled cellular replication (Gaëlle et al., 2007; 
Tong et al., 2016). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: E6 oncoprotein induced degradation of P53 (Adapted from Thomas, Pim and Banks, 1999 
and Narisawa-Saito and Kiyono, 2007). 
Ubiquitination of 
P53 
26 S proteasome complex 
P53 degradation 
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Association of HPV E7 oncoproteins with the tumour suppressor gene product, retinoblastoma 
(pRb) protein, leads to the dissociation of the pRb-E2F complex (Figure 1.2) (Giarrè, Caldeira, 
Malanchi, Ciccolini, Jo, Le & Tommasino, 2001; McLaughlin-Drubin & Münger, 2009; 
Narisawa-Saito & Kiyono, 2007). Unphosphorylated pRb binds to transcription factors such as 
E2F to inhibit cell cycle progression and therefore acts as a transcriptional repressor (Giarrè et 
al., 2001; McLaughlin-Drubin & Münger, 2009; Narisawa-Saito & Kiyono, 2007). G1 cyclin-
dependent kinases phosphorylate pRb, causing E2F to dissociate from pRb. E2F is thus no 
longer inhibited and can therefore promote cell progression to the S phase and activate 
transcription (Narisawa-Saito & Kiyono, 2007).  Binding of HPV E7 oncoproteins inactivates 
pRb resulting in the dissociation of bound E2F as well as the inability of pRb to bind to free 
E2F transcription factors causing cells to enter the S phase of the cell cycle prematurely (Giarrè 
et al., 2001; McLaughlin-Drubin & Münger, 2009; Narisawa-Saito & Kiyono, 2007). This 
leads to hyperproliferation and immortalization of infected cells (Giarrè et al., 2001; 
McLaughlin-Drubin and Münger, 2009; del Pino, Rodriguez-Carunchio and Ordi, 2013). 
 
 
 
 
 
 
 
 
 
 
 
1.6.2 Influence of HIV on HPV related vulvar carcinoma  
Immunosuppression is recognized as one of the risk factors for developing HPV associated 
diseases such as vulvar cancer. This may be due to the inability of the compromised immune 
system to fight the HPV infection (Marchetti, Comi, Bini, Rovati, Bai, Cassani, Ravizza, 
pRb inhibits E2F transcription 
factor to control cellular 
transcription 
HPV 
Free E2F activates uncontrolled 
transcription  
Figure 1.2: Interaction of E7 with pRb, activating E2F transcription factor (Adapted from 
Narisawa-Saito and Kiyono, 2007). 
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Tarozzi, Pandolfo, Dalzero, Opocher, Romagnoli, Carrassi, Bosari & d’Arminio Monforte, 
2013; Saidu, 2016). However, HIV infected cells also secrete a transactivator protein (Tat) and 
gp120 which disrupts the epithelial tight junctions, resulting in easier penetration of HPV into 
the target cells (Saidu, 2016). Patients infected with HIV are prone to infection with multiple 
HPV types, reactivation of latent HPV infection as well as HPV infection persistence  (Saidu, 
2016).  This may be due to continued immune suppression caused by HIV infection. HIV may 
also play a role in disease progression from HPV infection to squamous intraepithelial 
neoplasia and subsequent invasive carcinoma as HIV positive patients have increased uVIN 
prevalence, post-treatment disease recurrence, uVIN persistence and disease progression to 
invasive vulvar carcinoma (del Pino, Rodriguez‐Carunchio and Ordi, 2013; Preti, Sccurry and 
Marchitelli, 2014; Bradbury et al., 2016; Saidu, 2016). A recent study found that uVIN 
recurrence was significantly higher and also occurred earlier in HIV positive women (Bradbury 
et al., 2016). The same study also concluded that progression to invasive vulvar carcinoma 
occurred more frequently in younger HIV positive women (Bradbury et al., 2016).  
 
1.7 The use of FFPE derived nucleic acids for sensitive molecular application 
FFPE tissue is a rich resource of macromolecules and has therefore become more appealing for 
use in clinical research and molecular analysis. Nucleic acids extracted from FFPE tissue 
samples may be utilized for molecular biology studies in cancer research and genetic control 
of cell growth and differentiation as well as screening for genetic variations associated with 
diseases (Srinivasan et al., 2002). However, formalin fixation is known to have a deleterious 
effect on macromolecules such as DNA and RNA which may reduce the efficiency of 
downstream molecular applications.  
 
One of the major negative effects formalin fixation has on nucleic acids are fragmentation 
and/or degradation, which leads to decreased quantity and quality of nucleic acids extracted 
from FFPE specimens (Bass et al., 2014, Von Ahlfen et al., 2007). The average fragment length 
obtained from FFPE tissue is reported to be 300-400bp (Bonin et al., 2003; Huijsmans et al., 
2010). An additional negative effect is formalin-induced macromolecule modification through 
crosslink formation (Bass et al., 2014, Thavarajah et al., 2012), which often leads to a decrease 
in the utility of DNA and RNA in molecular assays such as genotyping (Baak-Pablo, et al., 
2010). Formalin interacts with macromolecules through the formation of covalent bonds 
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between formaldehyde and nucleophilic groups on amino acids or nucleic acid bases (Hoffman 
et al., 2015).  This leads to the formation of a methylol adduct that is subsequently converted 
to an unstable Schiff base (Hoffman et al., 2015).  Methylols or Schiff bases can chemically 
react with another functional group on another molecule leading to the formation of methylene 
bridges (Hoffman et al., 2015).  Nucleic acid-macromolecules crosslinks caused by formalin 
fixation in tissue may lead to impurities being co-extracted with nucleic acids and may result 
in decreased in efficiency of subsequent molecular applications such as qPCR (Huijsmans et 
al., 2010; Kapp et al., 2015, Ludyga et al., 2012). Nevertheless, recent advancements in 
extraction methods have led to improved nucleic acid quality and yield from FFPE tissue 
blocks which may therefore be suitable for sensitive downstream molecular assays such as PCR 
(Kokkat et al., 2013).  
 
1.8. Biomarker expression for vulvar carcinoma 
Currently, no screening method or test, such as the pap smear for cervical cancer, is available 
for vulvar cancer. This often leads to late diagnosis of vulvar cancer and subsequent severe 
treatment methods as the disease has already progressed.  On the other hand, these treatment 
methods may also cause overtreatment of patients with early diagnosis and where lymph node 
metastases have not yet occurred. For this reason, an increase in research on biomarkers for 
vulvar cancer diagnosis and prognosis is needed to indicate the severity and presence of vulvar 
cancer as well as to predict clinical behaviour and metastatic potential of the disease (Cao et 
al. 2016).   
 
A variety of studies have investigated p16ink4a as a prognostic biomarker in different cancer 
types with a recent meta-analysis suggesting that overexpression of p16ink4a may be associated 
with higher survival and better prognosis of vulvar carcinoma (Cao et al. 2016). According to 
Tringler et al., 2007 groin lymph node status was the strongest prognostic factor, while a recent 
study reported the most important prognostic factors in vulvar carcinoma is suggested to be the 
FIGO classification stage, lymph node metastasis and histological grade (Cao et al., 2016). 
Overexpression of p16ink4a was significantly associated with a FIGO stage of I-II, no lymph 
node metastasis, age of patient (<55) and HPV positive status (Cao et al., 2016). However, no 
correlation could be made between the overexpression of this biomarker and histological grade 
such as VIN I and VIN II (Cao et al., 2016).   Literature on the use of p16ink4a as surrogate 
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marker for HPV-induced vulvar carcinoma is limited as well as conflicted. Cao et al. (2016) 
concluded that p16ink4a correlates strongly with HPV positivity in vulvar carcinoma, while 
another study suggests that p16ink4a overexpression is not a surrogate marker for high-risk HPV 
types (Sznurkowski, Żawrocki and Biernat, 2016).   
 
The study of microRNAs as potential markers is well documented for a variety of cancers 
including cervical cancer but limited research is available on vulvar carcinomas (De Melo 
Maia, Lavorato-Rocha, Rodrigues, Coutinho-Camillo, Baiocchi, Stiepcich, Puga, Lima, Soares 
& Rocha, 2013; Yang & Wu, 2016). In a single study characterizing microRNA in vulvar 
carcinoma, 25 microRNAs were differentially expressed between HPV-positive and HPV-
negative carcinomas, while 79 altered microRNAs were observed in tumour tissue only, which 
was all down-regulated compared to adjacent normal tissue (De Melo Maia et al., 2013). 
miRNA-590-5p, a novel oncogenic miRNA in iVSCC, was found to be upregulated in 
association with lymphatic metastasis and research suggests that it may be a valuable 
therapeutic target in iVSCC (Yang & Wu, 2016). Different types of biomarkers such as 
proliferation markers, tumour suppressor genes, viral oncogenes and apoptosis markers have 
been investigated for diagnostic and prognostic value. However, clarification of the clinical 
value of these markers is lacking (Fons et al., 2007; Cattani et al., 2009; Knopp et al., 2009). 
This is due to the small number of studies being conducted on biomarkers for vulvar carcinoma, 
low sample size and absence of multivariate analysis in most of the studies (Knopp et al., 2009).  
 
Validation of biomarkers for diagnostic use requires a large sample size and is often time-
consuming and expensive (Knopp et al., 2009).  The use of tissue microarray technique (TMA) 
may effectively reduce costs and turnaround time as it allows for various molecular 
applications, including immunohistochemical (IHC) and in situ hybridization (ISH) analysis, 
of hundreds of different tissue samples simultaneously (Cardano, Diaferia, Falavigna, Spinelli, 
Sessa, DeBlasio & Biunno, 2013; Singh & Sau, 2010). The TMA technique allows for the 
construction of one FFPE tissue block containing a variety of FFPE tissue cores from different 
FFPE tissue blocks. This means that areas of interest from a big case with many FFPE blocks, 
for example, as is common in the case of vulvar cancer  diagnoses or target regions from 
different patients, can be analyzed at the same time using only one slide. The technique may 
be useful in the validation and verification of biomarkers, for example, tumour progression 
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studies where biomarker reaction is analyzed over the different stages of tumour progression 
such as VINI, VINII, VINIII and finally invasive vulvar cancer (Jain, 2018). Research 
regarding the sensitivity and specificity of the TMA technique could therefore be beneficial to 
the investigation on the prognostic and diagnostic value of new biomarkers for vulvar 
carcinoma and for the validation of these biomarkers for use in the clinical or diagnostic setting.   
 
1.9 Outline of this study 
The aim of this study was to identify the prevalent HPV strains in VIN and invasive iVSCC patients 
at Tygerberg Academic Hospital and to determine the expression of biomarkers in these 
malignancies.  
 
The objectives of this study are to: 
 (1) Identify the prevalent HPV strains through HPV subtype determination in patients diagnosed 
with LSIL (VIN I), HSIL (VIN II and VIN III) as well as iVSCC,  
(2) to correlate HPV strain prevalence results with HIV status, patient age, histological subtype and 
biomarker expression,  
(3) assess the expression of the high risk HPV E6/E7 oncoviral mRNA transcripts using 
quantitative real time PCR to detect transcriptionally active HPV infection, and 
(4) to assess the expression of well-known diagnostic marker p16INK4a in iVSCC FFPE tissue using 
IHC on full section and TMA slides to compare the results and assess the sensitivity and specificity 
of antibodies using the TMA technique, 
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Chapter 2   Materials and Methods 
 
2.1 Materials 
All materials used in this project are detailed in the methods section accompanied by the 
manufacturer and catalogues numbers. 
 
2.2 Methods 
2.2.1 Ethics approval 
Ethics approval for this study was obtained from the Undergraduate Health Research Ethics 
Committee at the Faculty of Medicine and Health Sciences at Stellenbosch (U17/08/038).  A 
waiver of consent was granted. Ethics approval was renewed annually throughout the duration 
of this study. 
 
2.2.2 Case selection and FFPE tissue block retrieval 
Data received from the Central Data Warehouse of the National Health Laboratory Service 
(NHLS) as well as clinical lists of cases diagnosed at Tygerberg Academic hospital from 
January 1997 to June 2018 were used to identify suitable cases for inclusion in this study. 
Criteria for inclusion in this study were: (i) FFPE tissue samples from patients with a diagnosis 
of vulvar intraepithelial neoplasia (VIN) or invasive vulvar squamous cell carcinoma (iVSCC), 
which were archived in the Division of Anatomical Pathology at Stellenbosch University/ 
NHLS, (ii) known age at the time of diagnosis, and (iii) sufficient representative tumour tissue 
available for DNA and RNA extractions.  All cases for which the FFPE tissue blocks could not 
be retrieved, cases with discrepant diagnosis after the secondary validation as well as FFPE 
blocks with insufficient representative tumour tissue were excluded from the study. The sample 
size required to achieve 95 % power, as determined with the help of a biostatistician and 
OpenEpi version 3.01 (Dean AG, Sullivan KM, Soe MM. OpenEpi: Open Source 
Epidemiologic Statistics for Public Health, Version. www.OpenEpi.com, updated 2013/04/06), 
were 72 FFPE tissue blocks representative of VIN and 68 tissue blocks representative of 
iVSCC diagnoses.  The HIV status of patients at the time of diagnosis, where available, was 
also recorded. 
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The original diagnosis was validated by a dedicated pathologist using representative 
hematoxylin and eosin (H&E) slides and a light microscope. Discrepant diagnoses were 
resolved in a secondary validation by a second pathologist. Additionally, H&E slides were also 
appraised for the presence of adequate representative tissue and visible HPV-induced changes 
such as the presence of koilocytes. The histological subtypes were recorded for each case. For 
tissue microarray construction, suitable tumour and normal tissue (where present) regions were 
demarcated on H&E slides using a permanent marker. All specimens were de-identified and a 
unique study number consisting of the diagnosis group and consecutive specimen number such 
as VIN-001 and VSCC-001 were allocated.  
 
2.2.3 Preparation of FFPE tissue sections using microtomy 
A rotary microtome (Leica Biosystems #RM2245, Wetzlar, Germany) was used to section the 
FFPE tissue blocks. Prior to sectioning, a sterile disposable scalpel was used to trim off excess 
paraffin around the embedded tissue, using a new scalpel for each block to minimize cross-
contamination. As the tissue blocks were exposed to air during storage, the first two tissue 
sections cut were discarded. The microtome and tools, such as forceps and brushes, were 
cleaned using 10 % (v/v) bleach and 70 % (v/v) ethanol after sectioning of each FFPE block.  
A new microtome blade was used to cut each FFPE tissue block. Two to four 10 µm sections 
were cut for respective DNA and RNA extractions. Sections of 3 µm thickness were cut for 
immunohistochemistry (IHC) analysis. The sections used for IHC were placed on a labelled 
positively charged Histobond+ adhesion microscope slide (Leica Biosystems catalogue# 
0810401) (Wetzlar, Germany) and left at room temperature (RT) to dry before staining 
procedures were done. Appropriate personal protective equipment (PPE) was used. 
 
 
2.2.4 Nucleic acid extraction 
FFPE tissue sections were dewaxed using deparaffinization solution (catalogue #19093) 
(Qiagen, Hilden, Germany). Total DNA was extracted using the QIAamp DNA FFPE Tissue 
Kit (Qiagen, Hilden, Germany) according to manufacturer’s recommendations. Briefly, tissue 
were lysed using ATL buffer and proteinase K. Samples were incubated overnight (at least 16 
hours) at 56 oC and immediately thereafter placed at 90 oC for 1 hour to aid the reversal of 
DNA crosslinks. Samples were spun at 11 000 x g in a benchtop centrifuge and the lower clear 
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phase were transferred to a clean 2 ml microcentrifuge tube. In order to digest residual RNA, 
2 µl of RNase 1 (10U/µl) (catalogue# EN0602) (Thermo Fisher Scientific, Life Technologies, 
USA) were added to each tube and incubated at 37 oC for 30 minutes. Buffer AL and molecular 
grade ethanol (catalogue #E7023) (Sigma-Aldrich St. Louis, MO, USA) were added to each 
sample and the lysates were transferred to a QIAamp minelute column. The columns were 
washed with buffer AW1 and buffer AW2, respectively and spun down at 11 000 x g for each 
step. Finally, DNA was eluted using a total volume of 75 µl ATE buffer. DNA was stored at -
20 oC until subsequent use.   
 
Total RNA was extracted using the miRNeasy FFPE tissue kit (catalogue #217504) (Qiagen, 
Hilden, Germany) according to the manufacturer’s instructions. Briefly, PKD buffer and 
proteinase K were added to each sample for tissue lysis. Samples were incubated at 56 oC for 
15 minutes followed by another 15 minute incubation step at 90 oC. The lower clear phase of 
the samples was transferred to a clean 2 ml microcentrifuge tube, incubated on ice for 3 minutes 
and then spun for at 20 000 x g 15 minutes. The supernatant were transferred to a clean 5 ml 
tube followed by the addition of DNase booster and DNase 1 to remove residual DNA. Samples 
were then incubated at room temperature for 15 minutes, after which buffer RBC and molecular 
grade ethanol (catalogue #E7023) (Sigma-Aldrich St. Louis, MO, USA) were added. The 
lysates were then transferred to minelute spin columns and spun at 8000 x g for 30 seconds 
until all of the fluid passed through the column. Columns were washed twice with Buffer RPE. 
RNA was eluted using 30 µl of nuclease free water and subsequently stored at -20oC until 
further utilization.  
 
2.2.5 Nucleic acid purity and quantity assessment 
Nucleic acid purity was assessed by measuring the A260nm/A280nm and A260nm/A230nm 
absorbance ratios using the Biodrop µLite spectrophotometer (Biodrop LTD, Cambridge, UK). 
The following categories specified in Table 2.1 were used to score the nucleic acid purity. 
 
 
 
Stellenbosch University https://scholar.sun.ac.za
19 
 
 
Table 2.1 Categories used for the assessment of nucleic acid purity.  
 
 
Nucleic acid concentrations were determined using the Qubit 3.0 fluorometer (Life 
Technologies, Thermo Fisher Scientific, California, USA) according to manufacturer’s 
recommendations.  The double-stranded DNA concentrations were measured using the Qubit 
dsDNA Broad Range Assay kit. RNA concentrations were measured using the Qubit RNA 
high sensitivity (HS) assay kit.  
 
2.2.6 Nucleic acid integrity assessment 
DNA integrity was assessed through amplification of the 205 bp human β-globin gene fragment 
using a SYBR green based quantitative Real-Time Polymerase Chain Reaction (qPCR) (Table 
2.2). The 10 µl qPCR reaction contained 100 ng DNA, 0.4 μM of the respective forward and 
reverse primers (Greer, Peterson, Kiviat, Manos & Ph, 1990), 1X PowerUpTM SYBRTM Green 
Master mix (Thermo Fisher Scientific, Life Technologies, USA) and nuclease free water. The 
PCR cycling conditions were 50 oC for 2 minutes, 95 oC for 2 minutes, 40 cycles at 95 oC for 
15 seconds and 60 oC for 1 minute. The dissociation curve conditions were 95 oC for 15 
seconds, 60 oC for 1 minute and 95 oC for 15 seconds according to manufacturer’s 
recommendations. Human genomic DNA (Cat# PRG3041) (Promega, Madison, WI, USA) and 
a non-template control (NTC) was used as positive and negative controls, respectively. All 
samples and controls were done in triplicate. 
 
 
 
 
Purity Category DNA A260nm/A280nm   RNA A260nm/A280nm  
DNA and RNA 
A260nm/A230nm 
I <1.8 <1.9 <2.0 
II 
1.8 to 1.9 
 (inclusive of values) 
Category II (1.9 to 2.0) 
(inclusive of values) 
2.0 to 2.2  
(inclusive of values) 
III >1.9 >2.0 >2.2 
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Table 2.2 Human β-globin (Greer et al., 1990) and  HPV subtype-specific (Karlsen, Kalantari, Jenkins, 
Pettersen, Kristensen, Holm, Johansson & Hagmar, 1996)  primer sequences and expected fragment 
sizes. 
Primer Primer sequence 
Expected 
fragment size 
β-globin: KM29 5’-GGT TGG CCA ATC TAC TCC CAG G-3’  
205 bp 
β-globin: PC04 5’-CAA CTT CAT CCA CGT TCA CC-3’ 
HPV 18 F 5’-CCG AGC ACG ACA GGA GAG GCT-3’  
172 bp 
HPV 18 R 5’-TCG TTT TCT TCC TCT GAG TCG CTT-3’ 
HPV 16 F 5’-ATA TAT GTT AGA TTT GCA ACC AGA GAC AAC-3’  
196 bp 
HPV 16 R 5’-GTC TAC GTG TGT GCT TTG TAC GCA C-3’ 
HPV 35 F 5’-CCCGAG GCA ACT GAC CTA TA-3’  
230 bp 
HPV 35 R 5’-GGG GCACAC TAT TCC AAA TG-3’ 
HPV 11 F 5’-ATG GAA AGT AAA GAT GCC TCC ACG T-3’  
200 bp 
HPV 11 R 5’-CAA CAG GCA CAC GCT GCA AG-3’ 
 
RNA integrity and fragment size distributions were assessed using the Agilent HS RNA kit on 
the Agilent® 2100 Bioanalyser (Agilent Technologies, California, United States of America). 
The RNA integrity number (RIN) and DV200 were used as quality indicators. RNA was 
deemed suitable for qPCR analysis a RIN score ≥ 2 and a DV200 score ≥ 30 %. In order to 
assess the adequacy of the RNA samples for use in qPCR as well as the presence of likely 
inhibitors of the qPCR reactions, RNA samples were reverse transcribed into cDNA, and the 
expression of the  human GAPDH mRNA transcript was investigated as described in section 
2.2.8.2. 
 
2.2.7 Detection of HPV DNA using qPCR 
Detection of HPV 16, 18, 35 and 11 DNA were done by  qPCR using HPV strain-specific 
primers (Karlsen et al., 1996) (Integrated DNA Technologies (IDT)) (Iwoa, USA) targeting the 
E7 genes (Table 2.2). The 10 µl qPCR reactions contained 100 ng DNA, 0.4 µM of the 
respective forward and reverse primers, 1X PowerUpTM SYBRTM Green Master mix 
(ThermoFisher Scientific, Life Technologies, USA) and nuclease free water. The PCR cycling 
conditions for amplification of HPV 18, 11 and 35 were 50 oC for 2 minutes, 95 oC for 2 
minutes, 40 cycles at 95 oC for 15 seconds and 60 oC for 1 minute. Amplification conditions 
for HPV 16 were similar with the exception of an annealing temperature of 55 oC instead of 60 
oC and an additional extension step for 1 min at 72 oC as recommended by the manufacturer. 
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The dissociation curve conditions were 95 oC for 15 seconds, 60 oC for 1 minute and 95 oC for 
15 seconds according to manufacturer’s recommendations. HPV plasmid DNA (HPV 16 
catalogue #45113D, HPV 18 catalogue #45152D, HPV 35 catalogue #40330, HPV 11 
catalogue #45151D) (ATCC, Manassas, United States of America) was used as respective 
positive controls while a NTC represented the negative control. qPCR reactions for all samples 
and controls were done in triplicate.  
 
2.2.8 Detection of HR HPV 16 and 18 E6/E7 mRNA transcripts 
2.2.8.1 Reverse transcription of total RNA samples into cDNA 
The High-Capacity cDNA Reverse Transcription kit (catalogue #4368814) (Life Technologies, 
Thermo Fisher Scientific, California, USA) was used to convert total RNA to cDNA, according 
to the manufacturer’s instructions. All reactions were done in duplicate. To detect possible 
carryover of residual genomic DNA in the qPCR reaction, a no reverse transcriptase (no-RT) 
reaction was included for each RNA sample. The 20 µl reverse transcription reaction contained 
300 ng RNA, 1X RT buffer, 4 mM dNTPs, 1X random primers, 1 µl of MultiScribe reverse 
transcriptase (50 U/µl), 1 µl of RNase inhibitor (20 U/µl) (catalogue# N8080119) (LTC Tech, 
Johannesburg, South Africa) and nuclease-free water. The cycling conditions for the reverse 
transcription reactions were 25 oC for 10 minutes, 37 oC for 120 minutes and 85 oC for 5 
minutes. The respective duplicate cDNA samples were pooled and used in subsequent qPCR 
analysis. 
 
 
2.2.8.2 Detection of human and viral HPV 16 and 18 E6/E7 mRNA transcripts 
The Quant Studio 5 real time PCR machine (Thermo Fisher Scientific, California, USA) was 
used for the analysis of mRNA transcript expression. As previously stated, the human GAPDH 
was used as a housekeeping gene as well as to give an indication of the adequacy of the RNA 
samples. The 20 µl GAPDH TaqMan gene expression assay reaction consisted of 2X TaqMan 
fast advance master mix (catalogue #4444557) (Life Technologies, Thermo Fisher Scientific, 
California, USA), 20 X TaqMan assay (catalogue #4331182) (Life Technologies, Thermo 
Fisher Scientific, California, USA) and nuclease free water. The HPV 16 and HPV 18 subtype-
specific primers and probe sequences were designed according to Lamarcq et al., 2002. The 
qPCR assays each contained 2X TaqMan fast advance master mix (catalogue #4444557) (Life 
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Technologies, Thermo Fisher Scientific, California, USA), 0.25 µM for each of the forward 
and reverse primers, 0.125 µM probe and nuclease-free water. Each qPCR reaction contained 
2 µl of pooled cDNA. cDNA reverse transcribed using RNA from HeLa and SiHa cells were 
used as HPV 18 and HPV 16 positive controls, respectively. The no template controls were 
used as negative controls. No-RT reactions of each RNA sample were included in the GAPDH 
assay reactions to detect possible residual genomic DNA. The qPCR reactions were done in 
triplicate for all samples and cycling conditions were 2 minutes at 50 oC and 2 minutes for 95 
oC for the hold stage, followed by the PCR stage of 40 PCR cycles at 95 oC for 1 second and 
20 seconds at 60 oC . 
 
2.2.9 Immunohistochemical staining using p16INK4a antibodies 
The BOND-III Fully Automated IHC and ISH Stainer (serial# 3211341) (Leica Biosystems, 
Wetzlar, Germany) was used for p16INK4a (catalogue# 805-4713) (Roche, Basel, Switzerland) 
IHC staining. All steps were carried out at room temperature unless otherwise stated. Briefly, 
FFPE tissue slides were deparaffinised using Bond Dewax Solution (catalogue# AR9222) 
(Leica Biosystems, Wetzlar, Germany) for 30 seconds (twice at 72 °C and once at room 
temperature), washed with alcohol for 30 seconds (three times) and then washed three times 
with Bond Wash solution (catalogue# AR9590) (Leica Biosystems, Wetzlar, Germany) for 30 
seconds (X3). Slides were then subjected to Bond Epitope Retrieval solution 2 (catalogue# 
AR9640) (Leica Biosystems, Wetzlar, Germany) for 30 seconds (twice) followed by a 20 
minute step at 100 °C and another 30 second step at room temperature. Samples were then 
washed with Bond wash solution (catalogue# AR9590) (Leica Biosystems, Wetzlar, Germany) 
for 30 seconds (four times) followed by a 3 minute wash step. The p16INK4a antibody) was then 
applied for 15 minutes followed by Bond Wash solution (catalogue# AR9590) (Leica 
Biosystems, Wetzlar, Germany) for 2 minutes, 1 minute and 1 minute, respectively. A post 
primary step was then applied for 8 minutes followed by three wash steps of 30 seconds each. 
The slides were then covered with BondTM polymer refine detection (catalogue# DS9800) 
reagent for 8 minutes followed by two wash steps of 2 minutes each using Bond wash solution 
(catalogue# AR9590) (Leica Biosystems, Wetzlar, Germany). Slides were then washed with 
deionized water for 30 seconds followed by incubation with peroxide block reagent for 5 
minutes. Slides were once again washed with Bond wash solution for 1 minute followed by 
two 30 second wash steps. Deionized water was then applied for 30 seconds followed by mixed 
DAB Refine once for 30 seconds and once for 10 minutes. The samples were washed three 
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times with deionized water for 30 seconds each and stained with Hematoxylin for 5 minutes. 
This is followed by deionized water for 30 seconds, Bond wash solution (catalogue# AR9590) 
(Leica Biosystems, Wetzlar, Germany) for 30 seconds and another deionized water step for 30 
seconds. IHC slides were then analysed blindly by a dedicated pathologist for p16INK4a 
positivity. 
 
2.2.10 Tissue Microarray (TMA) construction 
After sections were cut for DNA and RNA extractions, the leftover FFPE blocks were inspected 
for adequate tissue thickness for inclusion in the TMA construction. The H&E stained slides 
of full tissue sections were used to identify the representative regions of interest (tumour) for 
TMA production. The tape method was used tor TMA construction according to Glinsmann-
Gibson et al. (2019) (Figure 2.1 and Figure 2.2). Briefly, Formula R tissue embedding 
infiltration medium (catalogue #3801450) (Leica Microsystems, Wetzlar, Germany) was 
melted completely at 60 °C. Grid paper was attached to the base of a stainless steel mold 
(catalogue #4123) (Sakura Finetek Europe, AJ Alphen aan den Rijn, The Netherlands) using 
clear, double sided tape to aid in the alignment of the tissue cores. The marked H&E slides 
were then overlaid with the corresponding FFPE tissue blocks to identify where the tissue core 
should be taken. A 1 mm core was then taken from the respective FFPE tissue blocks using the 
UNITMA microarayer (catalogue #IW-UT06) (IHC World, Ellicott City, United States of 
America). For each sample included in the TMA, the FFPE core was then slowly released from 
the microarrayer and a needle stick was used to pick up the core and place it in the pre-identified 
location on the grid paper in the base mold. After each FFPE tissue core were extracted and 
placed in the desired position, the base mold is covered with a uni-cassete (catalogue #4157) 
(Sakura Finetek Europe, AJ Alphen aan den Rijn, The Netherlands). Small weights were placed 
on two corners of the cassette and the mold was gently filled with liquid paraffin. The TMA 
block was left at room temperature for 30 minutes to cool and another 30 minutes at 4 °C to 
ensure the paraffin block was properly set. The base mold was then removed and the FFPE 
TMA block was cut as described in section 2.2.3.
Stellenbosch University https://scholar.sun.ac.za
24 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.11 Statistical analysis 
Data was analysed using IBM® SPSS® statistics version 25 (IBM Corp. Released 2017, IBM 
SPSS Statistics for Windows, Version 25.0; Armonk, NY: IBM Corp) and Stata version 15.1. 
HPV genotyping data and other categorical variables were summarised using frequencies and 
proportions. Association between HPV strains (i.e. presence/absence) and categorical variables 
such as HIV status and p16INK4a biomarker expression (coded as either positive or negative) 
were assessed using Chi-Square test. The strength of the relationships was quantified using a 
correlation coefficient. All statistical tests were performed at 5 % level of significance and 95 
% confidence intervals will be reported. Sensitivity and specificity of the TMA slide was 
evaluated using full section slides as the gold standard using EpiCalc 2000 (Version 1.02, 
Gilman and Matt, 1998). 
 
Figure 2.1 Illustration of an example of a TMA map. 
Figure 2.2 Example of the paper grid used to aid in 
alignment of tissue cores (Glinsmann-Gibson et al., 
2019).  
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Chapter 3   Results and Discussion 
 
3.1 Specimen selection and validation 
Approximately 2 500 possible VIN and iVSCC cases diagnosed at Tygerberg Academic 
Hospital between January 1997 to June 2018 were obtained from clinical lists and data from 
the NHLS central data warehouses. Of these plausible cases, merely 312 had suitable diagnosis 
and were available for retrieval as the NHLS at Tygerberg Academic Hospital only stored H&E 
slides from 2003. The H&E slides of cases prior to 2003 were no longer available as these were 
discarded by the NHLS according to their standard operating procedures and policies regarding 
long term specimen storage. Therefore, the cases included in this study were from the time 
period of January 2003 to June 2018. A total of 82 cases had discrepant diagnoses upon 
validation and were re-validated by a second pathologist. Of these, 47 cases were excluded 
from the study as no consensus could be reached on the diagnosis after the secondary 
validation.  
 
The population size (N) for this study was defined as the number of suitable cases diagnosed 
with VIN and iVSCC, respectively and for which the FFPE tissue blocks were retrieved from 
the NHLS archive, that is, the number of tissue blocks in-hand. The population proportion 
required for a 95 % confidence level was calculated as 72 FFPE tissue blocks representative of 
VIN and 68 tissue blocks representative of iVSCC. Therefore, enough FFPE tissue blocks for 
both diagnosis groups were obtained for the study to have 95 % power. Clinical information 
such as age of the patient at the time of diagnosis, HIV status and histopathological subtype 
were also recorded where possible. All specimens included in this study had sufficient tumour 
and/or pre-cancerous tissue required for RNA and DNA extractions and thus met the selection 
criteria. Specimens were de-identified by allocating a unique study number for example VIN-
001 or VSCC-001. 
 
 
3.2 Analysis of age and HIV status of women diagnosed with VIN and iVSCC 
As previously mentioned, VIN and invasive vulvar carcinoma incidence have increased over 
the last few years with the affected patients being of a much younger age (Bradbury et al., 
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2016; De Vuyst et al., 2009). Increased diagnosis in younger populations may be due to high 
HIV prevalence as immunosuppression is one of the major risk factors for developing HPV 
related diseases (Bradbury et al., 2016). HIV infection also accelerates the progression of VIN 
to invasive vulvar carcinoma which may lead to increase iVSCC diagnosis in younger women 
(Auvert, Marais, Lissouba, Zarca, Ramjee & Williamson, 2011; Bradbury et al., 2016). In order 
to ascertain the age distribution in our population, the age of women at diagnosis was assessed 
and correlated to HIV status.  Other features such as histopathological subgroups were also 
compared to HIV status to investigate the role of HIV in the development of VIN and iVSCC.  
 
3.2.1 Younger women were more frequently diagnosed with VIN and iVSCC 
Data analysis using the Pearson Chi-square test showed no significant difference (p>0.05) in 
the age at which patients were diagnosed with pre-cancerous lesions and invasive squamous 
cell carcinoma of the vulva (Figure 3.1 and Table 3.1). A similar trend for both diagnosis 
groups was observed, with the mean ages being 49.4 ±17.5 years ranging from 23 to 88 years 
for VIN, and 49.3±14.9 within a range of 24 to 83 years for iVSCC (Figure 3.1).  
VS
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Figure 3.1: Age distribution of women diagnosed with VIN and VSCC. This box and whisker plot 
illustrates the distribution of the ages centred on the respective population means of patients diagnosed with VIN 
and iVSCC. 
Results show that 41.7 % (30/72) of patients diagnosed with VIN and 54.4 % (37/68) of those 
diagnosed with iVSCC were between the ages of 36 to 59 years (Table 3.1). Moreover, a 
proportion of women were 35 years and younger, that is, 28 % (20/72) of these particular 
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women were diagnosed with VIN and 19 % (13/68) with iVSCC (Table 3.1). Only 30.6 % 
(22/72) VIN and 26.4 % (18/68) iVSCC patients were older than 60 years at the time of 
diagnosis. However, of these, only 7 % (5/72) and 3 % (2/68) were older than 75 for the 
respective VIN and iVSCC diagnoses. Our data thus show that women diagnosed with vulvar 
carcinoma and its precursors in our study population at Tygerberg Academic Hospital were 
generally younger than 59 years, with 69 % (50/72) receiving a diagnosis of VIN and 73 % 
(50/68) with iVSCC.  Our results are therefore in accordance with the findings of the clinical 
study also done at Tygerberg Academic Hospital but between 1 January 2001 and 31 December 
2014, by Butt and Botha (2017). Their results showed that the mean age of patients diagnosed 
with HPV-related vulvar cancer and its precursors during the indicated time period were 50,4 
years.  Overall, our findings are contrary to reported international studies where the mean age 
of women diagnosed with VIN and iVSCC is 64 and 70 years. Our results indicate that the 
majority of women whose specimens were included in this study received a diagnosis of VIN 
and iVSCC at a much younger age with a large proportion being even younger than 35.  
 
 
Table 3.1: The average age and number of HIV positive and HIV negative patients as well 
as patients with unknown HIVstatus for each age group per diagnosis.  
Diagnosis Age group 
 HIV status 
Total  
 (mean age±SD) 
Negative  
(mean age±SD) 
Positive  
(mean 
age±SD) 
Unknown 
(mean±SD) 
VIN 
18-35 20 (29.5±3.3) 2 (29.5±0.7) 16 (30.1±3.3) 2 (25±0.0) 
36-59 30 (46.7±6.4) 6 (49.3±7.5) 17 (43.9±5.6) 7(51±4.4) 
60-75 17 (67.2±4.9) 9 (66.3±5.5) 2 (71.5±0.7) 6 (67.2±4.5) 
>75 5 (85±3.9) 0 0 5 (85±3.9) 
Total 72 (49.4±17.5) 17 (56.0±14.0) 35 
(39.2±11.5) 
20 
(61.8±18.7) 
iVSCC 
18-35 13 (31.1±3.7) 0 13 (31.1±3.7) 0 
36-59 37 (46.1±8.1) 18 (50.3±7.7) 19 (42.2±6.5) 0 
60-75 16 (67.3±5.4) 12 (69.0±5.1) 4 (62.3±2.1) 0 
>75 2 (81.0±2.8) 2 (81.0±2.8) 0 0 
Total 68 (49.3±14.9) 32 (59.2±12.5) 
36 
(40.4±10.7) 
0 
 
3.2.2 Age of VIN and iVSCC patients according to HIV status 
As stated previously, HIV is known to exacerbate HPV related diseases as HIV positive women 
are more likely to contract HPV and also have the propensity for rapid disease progression 
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(Auvert et al., 2011; Williamson, 2015).  In our study, the iVSCC group comprised of 52.9 % 
(36/68) HIV positive and 47.1 % (32/68) HIV negative patients (Table 3.1). On the other hand, 
the VIN group included 48.6 % (35/72) HIV positive, 23.6 % (17/72) HIV negative and 27.8 
% (20/72) of patients with unknown HIV status (Table 3.1). The proportion of samples of 
patients with unknown HIV status was thus excluded from the analysis pertaining to HIV 
status. Results showed that 88.9 % (32/36) of HIV positive patients with iVSCC and 94.3 % 
(33/35) of HIV positive patients with VIN were younger than 59 years old (Table 3.1). HIV 
positivity was thus the highest in younger age groups with 45.7 % and 48.6 % of HIV positive 
VIN patients being between the ages of 18 to 35 and 36 to 59 years respectively, while 36.1 % 
and 52.8 % of iVSCC patients for the respective age groups were HIV positive (Table 3.1). 
Using the Pearson Chi-square test, a significant relationship between HIV status and age of 
patients diagnosed with VIN and  iVSCC in our sample population was established (p<0.05). 
The majority of patients for both VIN and iVSCC categorized in the older age groups were 
HIV negative.  
 
 
3.3 Nucleic acid purity and quality assessment 
Formalin fixation of tissues is known to result in macromolecule modification through cross-
link formation, fragmentation and degradation of extracted nucleic acids that leads to decreased 
quantity and quality, which in turn may affect downstream molecular applications (von Ahlfen, 
Missel, Bendrat & Schlumpberger, 2007; Baak-Pablo, Dezentje, Guchelaar & van der Straaten, 
2010; Bass, Engel, Greytak & Moore, 2014; Thavarajah, Mudimbaimannar, Rao, Ranganathan 
& Elizabeth, 2012). Human and viral nucleic acids templates of subpar quantity and quality 
may interfere with sensitive PCR-based applications such as genotyping. Therefore, to obtain 
successful and meaningful results, the quantification and quality assessment of FFPE-derived 
nucleic acids are essential to gauge suitability for qPCR and genotyping. 
 
3.3.1 Nucleic acid purity assessment 
DNA and RNA isolated from FFPE vulvar tissue were evaluated using a Biodrop μLite and a 
Qubit 3.0 fluorometer. Indicators used for purity assessment were the A260nm/A280nm and 
A260nm/A230nm spectrophotometric absorbance ratios which were each classified into 
categories as indicated in Table 2.1. The generally accepted A260nm/A280nm ratios for pure 
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DNA and RNA are 1.8 and 2.0, respectively. An A260nm/A280nm ratio less than 1.7 indicates 
protein contamination.  The A260nm/A230nm ratio is an ancillary measurement of pure nucleic 
acids where values between 2.0 and 2.2 indicate pure DNA or RNA, whilst values less than 2.0 
suggest the presence of contaminants such as residual nucleic acid extraction reagents (Ludyga, 
et al., 2011).   
 
All samples yielded pure DNA fit for utilization in PCR reactions. The average A260nm/A280nm 
ratios (Figure 3.2 A and Table 3.2) for VIN DNA samples were 1.91±0.08 and data ranging 
from 1.68 to 2.15. The DNA extracted from iVSCC samples also had an average of 1.91 but 
with a standard deviation 0.10 and data ranged from 1.81 to 2.02. VIN and iVSCC DNA 
samples had an average A260nm/A230nm reading (Figure 3.3 A and Table 3.3) of 2.38±0.18 and 
2.23±0.79, respectively. Hence, the majority of the extracted DNA, irrespective of diagnosis 
group, could be classified as either category II and III of the A260nm/A280nm ratios, with only 
4 VIN and 1 iVSCC samples falling into category I. A similar trend was observed for the 
A260nm/A230nm ratios as most samples fell into categories I and II, with 8 of the VIN and 7 of 
the iVSCC samples being assigned to category III. These results, with the exception of a few 
outliers, indicated that pure DNA, free of protein contamination and with minimal reagent 
carryover, was isolated. The average DNA yields for VIN and iVSCC samples were 5 µg and 
9 µg, respectively. All samples thus had sufficient DNA yield and were included in this study 
as the minimum amount of DNA needed was 1.5 µg. 
 
VIN and iVSCC RNA samples had an average A260nm/A280nm ratio (Figure 3.2 B and Table 
3.2) of 1.89±0.06 and 1.92±0.04 as well as an A260nm/A230nm ratio (Figure 3.3 B and Table 
3.3) of 1.84±0.33 and 1.94±0.24, respectively.  Contrary to the DNA A260nm/A280nm ratio 
categorisation, most RNA samples were assigned to categories I and II (Table 3.2), with only 
one sample in each diagnosis group being in category III. Similarly for the A260nm/A230nm, 
most RNA samples were categorised in categories I and II, with 5 VIN and 6 iVSCC being 
assigned to category III (Table 3.3). As in the case with the extracted DNA, these results, with 
the exception of a few outliers, suggested that pure RNA was extracted from FFPE vulvar 
tissue. The average RNA yield were substantially less than that of DNA with VIN samples 
having an average yield of 1.5 µg and iVSCC samples an average of 2.3 µg. 
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Figure 3.2: DNA (A) and RNA (B) A260nm/A280nm purity results. This figure shows the 
distribution of A260nm/A280nm ratios for nucleic acids extracted from VIN and iVSCC samples. 
 
 
Table 3.2: Proportion of DNA and RNA samples divided into purity categories according to 
the A260nm/A280nm ratio. 
 
 
A minimum of 0.9 µg RNA per sample (300 ng x 3 reactions) was needed for efficient cDNA 
conversion. Therefore, 11 VIN samples and 2 iVSCC samples were excluded from qPCR 
analysis due to insufficient RNA yield. Furthermore, all samples included for HPV genotyping 
analysis thus had sufficient nucleic acid concentrations. 
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Figure 3.3: DNA (A) and RNA (B) A260nm/A230nm purity results. This figure shows the distribution of 
nucleic acid purity results according to the A260nm/A230nm ratios for VIN and iVSCC. 
 
 
Table 3.3: Proportion of DNA and RNA samples divided into purity categories according to 
RNA RNA A260nm/A230nm ratio. 
 
 
 
 
 
 
 
 
3.3.2 DNA integrity 
DNA integrity was determined by the amplification of a 205 bp fragment of the highly 
abundant human β-globin gene using qPCR. As FFPE-derived DNA is often highly 
fragmented, amplification of the β-globin fragment was used as verification of the ability to 
obtain amplicons of around 205 bp as well as to verify the sufficiency of human DNA. In 
addition, the successful amplification of the β-globin fragment also indicated that there was no 
interference of any possible PCR inhibitors. This would thus demonstrate that the FFPE-
V
IN
VS
C
C
0
2
4
6
8
10
Specimen diagnosis
A
2
6
0
n
m
/A
2
3
0
n
m
 Sample type 
 DNA A260nm/A230nm RNA A260nm/A230nm 
 VIN (n = 72) iVSCC (n = 68) VIN (n = 72) iVSCC (n = 68) 
Category I 
(<2.0) 
8 7 51 42 
Category II 
(2.0 to 2.2) 
inc 
14 13 16 20 
Category III 
(>2.2) 
50 48 5 6 
Average ratio 2,38 (±0,79) 2,23 (±0,18) 1.84 (±0.33) 1.94 (±0.24) 
A B 
Stellenbosch University https://scholar.sun.ac.za
32 
 
 
derived DNA was suitable for use in qPCR analysis, especially for amplification of other gene 
fragments of similar sizes. This particular β-globin fragment was chosen as it was 
approximately of similar size as all of the HPV amplicons to be analysed (Table 2.1). 
 
For the analysis of the qPCR reactions, the same threshold was used to assess amplification of 
all samples. The dissociation curve and melting temperature of the human DNA positive 
control as well as a Ct value of ≤36 were used to confirm the successful amplification of the 
unknown samples. No amplification was observed in NTCs. The 205 bp human β-globin gene 
fragment could be amplified in 100 % (72/72) of VIN as well as 100 % (68/68) of iVSCC 
samples. All extracted DNA samples were therefore included for analysis as the β-globin 
fragment was amplified successfully in all samples, indicating that the samples were of 
adequate DNA integrity for use in PCR-based HPV genotyping.  
         
3.3.3 RNA integrity 
RNA integrity was measured using the Agilent 2100 Bioanalyzer and the Agilent Nano 6000 
total RNA kit. The RNA integrity number (RIN) was generated as an indication of intact and 
degraded RNA. Generally, a RIN value of 1 indicates severely degraded RNA while a value of 
10 represents highly intact RNA. Another measurement of RNA quality used is the DV200 
score which measures the percentage of fragments ranging between 200 and 8000 bp. RNA 
was deemed of good quality if it had a minimum RIN score of 2 and a DV200 score of more 
than 30 % (Yakovleva et al., 2017, Technical note: RNA sequencing, Illumina, 2016). 
Although the RIN value of an RNA sample is a reliable metric to evaluate RNA integrity for 
standard RNA sequencing, the DV200 score adds more value to evaluating RNA integrity of 
samples derived from FFPE tissue as these samples can be much more challenging due to 
sample degradation (Graf, 2017). The DV200 score thus gives an indication of the percentage 
of fragments in the RNA sample which are larger than 200 nucleotides.  
 
As is tabulated in Table 3.4, the majority of VIN and iVSCC samples had a DV200 score of 30 
% to 50 % and 50% to 70 % suggesting that a good proportion of RNA samples contained 
fragments larger than 200 nucleotides and thus were not severely degraded. However, 1 out of 
72 VIN and 4 out of 68 iVSCC samples had a DV200 score of less than 30 %. A greater 
proportion of VIN and iVSCC samples had a RIN value of >2 (Table 3.5), suggesting that RNA 
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was fragmented. The proportion of VIN and iVSCC samples with a RIN value less than 2 were 
12 in 72 and 3 in 68, respectively. 
 
Table 3.4 The proportion of VIN and iVSCC RNA samples categorised according to DV200 
scores. 
DV200 Category VIN (n = 72) iVSCC (n=68) 
<30 % 1 4 
30 %-50 % 32 26 
50 %-70 % 38 37 
>70 % 1 1 
 
 
Table 3.5 Proportion of VIN and iVSCC RNA samples categorised according to RIN score. 
RIN score VIN (n = 72) iVSCC (n=68) 
<2 12 3 
2-3 59 65 
>3 1 0 
Average RIN 
score (SD) 2.2 (±0.4) 2.31 (±2.5) 
 
Samples deemed fit for use in qPCR analysis were subjected to cDNA conversion and the 
expression of the human GAPDH mRNA transcript was evaluated as an indication of specimen 
sufficiency and for the presence of possible qPCR reaction inhibitors. The presence of residual 
genomic DNA was assessed through the amplification of RNA samples subjected to cDNA 
conversion with no reverse transcriptase added to the reaction. Expression of GAPDH mRNA 
was evaluated using the same threshold for all samples tested as well as a Ct value of ≤36. 
GAPDH was amplified in 100 % (61/61) VIN and 100 % (66/66) iVSCC samples included in 
the analysis, confirming that the FFPE-derived RNA was suitable to use in qPCR. Residual 
genomic DNA was not detected in any of the no-RT controls; hence all samples identified for 
use in RNA analysis were included.  
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3.4 Detection of HPV DNA in FFPE vulvar tissue  
 
3.4.1 HPV prevalence in VIN and iVSCC  
The prevalence of HPV 16, HPV 18, HPV 35 and HPV 11 in FFPE vulvar tissue from patients 
diagnosed with VIN and iVSCC were tested with qPCR using DNA samples and HPV type-
specific primers  targeting the respective E7 gene regions (Karlsen et al., 1996). Reported HPV 
prevalence results varied from study to study and are largely dependent on the geographical 
site. Overall, HPV DNA was detected in 77.8 % (95 % confidence intervals (CI): 66.4 % – 
86.7 %) of VIN and 66.2 % (95 % CI: 53.7 % – 77.2%) of iVSCC samples (Table 3.6).  HPV 
16 DNA was more frequently detected in both diagnosis groups compared to the other HPV 
strains and could be amplified in 69.4 % (95 % CI:57.4 % – 79.8 %) of VIN and 57.3 % (95 % 
CI: 44.7 % – 69.3 %) of iVSCC samples (Table 3.6). Therefore, results indicate that HPV 16 
is the most prevalent HPV subtype detected in our sample population, being detected in slightly 
more VIN samples than iVSCC. This result correlates with that of De Sanjosé et al., 2013 
which found that HPV 16 had a higher prevalence in VIN samples than in iVSCC samples. 
According to De Sanjosé et al., 2013,  this finding is contrary to what is observed in cervical 
HPV-related lesions where a higher HPV 16 prevalence is seen in more advanced disease.  
 
On the other hand, HPV 18 DNA were present in a higher number of iVSCC samples compared 
to VIN with amplification in 10.3 % (95 % CI: 4.2 % – 20.1 %) of iVSCC and 4.2 % (95% CI: 
0.9 % – 11.7%) of VIN samples (Table 3.6), which is also in concordance to that described in 
De Sanjosé et al., 2013 for HPV 18 detection on iVSCC and VIN cases. Furthermore, HPV 11 
were detected in 11.1% (95 % CI: 4.9 % – 20.7 %) of VIN samples and 5.9 % (95 % CI: 1.6 % 
– 14.3 %) of iVSCC samples (Table 3.6). The least abundant HPV strain detected in our sample 
population was HPV 35 as it was detected in 4.2 % (95 % CI: 0.9 % – 11.7 %) of VIN samples 
and in none of the iVSCC samples (Table 3.6). Although the majority of VIN and iVSCC 
samples had single HPV infection, more than one HPV type could be amplified in 7 VIN and 
5 iVSCC samples. For VIN samples, co-infection with HPV 16 and HPV 11 were detected in 
4 samples, whereas co-infections with HPV 18 and HPV 11 as well as HPV 16 and HPV 35 
could be detected in 1 sample each. Additionally, a co-infection with HPV 16, HPV 35 and 
HPV 11 was identified in one of the VIN samples. The detection of both HPV 16 and HPV 18 
DNA was observed in three iVSCC samples, while HPV 18 and HPV 11 as well as HPV 16 
and HPV 11 could be detected in one iVSCC sample each.  Our HPV DNA detection results is 
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also in agreement with Mbulawa et al., 2016 who concluded HPV 16 and HPV 18 to be the 
most prevalent high risk HPV strains among South African women. However, a study done 
among Nigerian women concluded that HPV 18 and 16 prevalence were low in this population 
(Akarolo-Anthony, Famooto, Dareng, Olaniyan, Offiong, Wheeler & Adebamowo, 2014). This 
study done by Akarolo-Anthony et al., 2014 also found HPV 35 to be the most prevalent strain 
among Nigerian women using cervical samples, while HPV 35 was the least abundant DNA to 
be detected in our study population. Our findings show that the HPV prevalence in our study 
population differ to that in other African countries such as Nigeria and thus could support the 
idea of variable HPV strain prevalence in different geographical areas if a larger South African 
population is studied in future.  
 
Table 3.6: HPV strain prevalence in VIN and iVSCC samples. This table indicates the overall HPV 
DNA detection as well as HPV strain specific prevalence in VIN and iVSCC samples. 
Sample type HPV 16 HPV 18 HPV 35 HPV 11 
*HPV 
infection 
VIN (n=72) 50 (69.4 %) 3 (4.2 %) 3 (4.2 %) 8 (11.1 %) 56 (77,8 %) 
iVSCC (n=68) 39 (57.3 %) 7 (10,3 %) 0 (0 %) 4 (5.9 %) 45 (66,2 %) 
*All samples with one or more HPV strain detection. 
 
 
The inability to detect HPV DNA in some samples may not be an indication that HPV infection 
is absent in these samples, but could possibly be attributed to several explanations. One of the 
major factors which may lead to unsuccessful amplification could be the use of degraded DNA 
templates, such is characteristic of FFPE DNA. However, as extensive quality assessment of 
the extracted FFPE DNA was done and all DNA samples were found fit for use in qPCR, this 
might thus be an unlikely reason. The human β-globin gene fragment was successfully 
amplified for all FFPE DNA samples, which also confirms that the integrity of the samples as 
well as the ability to amplify fragments of around 205 bp. Another reason for undetectable 
HPV DNA may be the low abundance of HPV DNA, which could be ascribed to low HPV 
DNA co-extraction with human DNA, especially considering the formation of formalin-
induced crosslinks between nucleic acids and proteins in fixed tissue. If HPV DNA was too 
low, it may also have been below the detection range of the qPCR assay, which could then 
have led to a “negative” HPV DNA result.  Another plausible reason could be that tissue 
samples for which HPV DNA were not detected could have been infected with different HPV 
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subtypes than those tested for. Therefore, additional investigations using a broader range of 
HPV subtypes are warranted. 
 
3.4.2 Correlation of HPV DNA detected and histological subtypes 
As part of the histological analysis, VIN and iVSCC diagnoses are also further classified into 
histopathological subgroups.  In our study population the VIN group consisted of 8 LSIL (low-
grade lesion) and 64 HSIL (high-grade lesion) samples. The VSCC group were further 
categorized into 5 warty, 7 basaloid, 14 non-keratinizing and 42 keratinizing samples (Table 
3.7). According to literature, HPV is more readily associated with warty and basaloid iVSCC 
subtypes while the keratinizing variants are often linked to absence of HPV infection (Knopp 
et al., 2009; Preti, Sccurry and Marchitelli, 2014). VIN and iVSCC histological subtype 
classifications were therefore compared to HPV DNA detection (Table 3.7).  
 
For the VIN subgroups, HPV could be detected in 37.5 % of LSIL (VIN I) and 82.8 % of HSIL 
(VIN II and VIN III). A reason for the lower HPV detection rate in LSIL samples compared to 
that of HSIL could be due to possible clearing of the HPV infection in these samples.  The 
observation of increased HPV 16 infection frequency in lower grade lesions compared to more 
advance disease, is in contradiction to the findings of De Sanjosé et al. (2013), where it is found 
that HPV 16 prevalence were higher in advanced cervical disease. 
 
Results showed that HPV was detected in 60 % (3/5) of warty iVSCC and 57.1 % (4/7) of 
basaloid iVSCC samples (Table 3.7). However, although the sample numbers are low, this high 
HPV detection rate in warty and basaloid VSCC samples are consistent with literature findings 
(Faber, Sand, Albieri, Norrild, Kjaer & Verdoodt, 2017). HPV DNA was detected in 66.7 % 
(28/42) of keratinizing iVSCC samples (Table 3.7). This is in contrast to the literature  as 
prevalence rates of only 4 % to 21 % of keratinizing iVSCC samples have been previously 
reported to be associated with HPV (Madeleine, Daling, Schwartz, Carter, Wipf, Beckmann, 
McKnight, Kurman, Hagensee & Galloway, 1997). Though, more recent reviews also reported 
HPV DNA to be associated with keratinizing iVSCC. Faber et al. (2017) reported that a mere 
13.2 % of keratinizing cancerous vulvar lesions were HPV positive, whereas, Pils et al., 2017 
indicated that 10 % of their keratinizing vulvar samples compared to 77 % of samples with a 
warty or basaloid morphology were infected with HPV. Additionally, 71.4 % (10/14) of non-
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keratinizing iVSCC samples in our study population tested positive for HPV DNA (Table 3.7). 
However, of the women diagnosed with iVSCC, 18 of them were older than 60 years. Notably, 
15 of these 18 cases were histologically classified as keratinizing and/or non-keratinizing 
iVSCC and of these, HPV DNA was not detected in 10 samples.  Considering the advanced 
age of these women and the lack of HPV DNA detection, these few cases most likely represent 
HPV independent iVSCC. Background dermatitis with or without dVIN was not correlated for 
in these cases. As previously stated, diagnosis of dVIN is challenging. The small number of 
cases again highlights the difference in epidemiology of the two aetiopathogenic pathways in 
first world versus developing countries. Nonetheless, a diagnosis of dVIN is rare at Tygerberg 
Academic Hospital and further investigation is needed (personal communication, Dr R. 
Razack). 
 
Correlation of the histological subtype with the specific HPV genotypes showed that HPV 16 
was detected in a significant proportion of VIN samples (69.4 %; 50/7; P <0.05) compared to 
the iVSCC samples (Table 3.6). A similar observation was made for HPV 11 that was detected 
in significantly more VIN samples (11.1 %; 8/72; P<0.05) than in samples with the iVSCC 
diagnosis (Table 3.6).    
 
Our findings indicated that, in contrast to available literature, a higher HPV prevalence was 
observed in our keratinizing and non-keratinizing iVSCC samples (Table 3.7).  Additionally, 
results also suggested that the relationship between HPV infection and vulvar iVSCC 
histopathological subtypes might differ to that in other geographical regions.  
 
Table 3.7: Comparison of VIN and iVSCC diagnosis subgroups with HPV DNA detection.  
  
iVSCC subtype VIN subtype 
Keratinizing non keratinizing warty basaloid LSIL HSIL 
HPV detected 28/42 (66.7 %) 10/14 (71.4 %) 3/5 (60 %) 4/7 (57.1 %) 3/8 (37.5 %) 53/64 (82.8 %) 
HPV 
Undetected 
14/42 (33.3 %) 4/14 (28.6 %) 2/5 (40 %) 3/7 (42.9 %) 5/8 (62.5 %) 11/64 (17.2 %) 
 
 
Stellenbosch University https://scholar.sun.ac.za
38 
 
 
3.4.3 Comparison of the HPV subtype DNA detected with HIV status 
A compromised immune system is one of the major risk factors for HPV infection. According 
to literature, HIV infection promotes the progression of an HPV infection to an intraepithelial 
lesion and subsequently into invasive squamous cell carcinoma (Saidu, 2016). The presence of 
HPV DNA was correlated with HIV status (Table 3.8). Only samples from patients with known 
HIV status, albeit positive or negative, were included in this analysis. A total of 41 VIN and 
45 iVSCC patients had a general HPV infection; of these 70.7 % (95 % CI: 54.4 – 83.8 %) of 
VIN and 57.8 % (95 % CI: 42.3 – 72.3 %) of iVSCC samples had a HIV co-infection (Table 
3.8).  For VIN cases with HPV 16 infection, the percentage of HIV positive patients were 
higher (46 %) than for HIV negative (24 %) (Table 3.8). No significant difference was seen in 
the proportion of iVSCC cases with HPV 16 DNA detected and HIV status (Table 3.8). 
Although the detection rate for HPV 18 was low, it was found that all 3 of the VIN samples 
and all 7 of iVSCC samples were from HIV positive patients.  Both VIN samples in which 
HPV 35 was detected were also HIV positive.  Likewise, 87.5 % (7/8) of VIN and 100 % (4/4) 
iVSCC samples positive for HPV 11 had a HIV co-infection. However, a Pearson Chi-square 
test revealed no significant difference between HIV positive and HIV negative VIN and iVSCC 
samples for which HPV was detected.   
 
Of the cases for which multiple HPV strains were detected, 5 of the 7 VIN samples and all 5 
iVSCC samples were from HIV positive patients (refer to 3.5.1). This result is in concordance 
with available literature which states that HIV infection increases the risk of multiple HPV 
infection (Lissouba, Van de Perre & Auvert, 2013).  
 
Table 3.8: HPV subtype detection compared to HIV status. 
 
VIN iVSCC 
HPV type HIV positive HIV negative HIV positive HIV negative 
16  23/35 (66 %) 12/35 (34 %) 20/39 (51 %) 19/39 (49 %) 
18 3/3 (100 %) 0/3 (0 %) 7/7 (100 %) 0/7 (0 %) 
35 2/2 (100 %) 0/2 (0 %) 0/0 (0 %) 0/0 (0 %) 
11 7/8 (87.5 %) 1/8 (12.5 %) 4/4 (100 %) 0/4 (0 %) 
HPV 
prevalence 
29/41 (70.7 %) 12/41 (29.3 %) 26/45 (57.8 %) 19/45 (42.2 %) 
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3.5 Evaluation of HPV 16 and HPV 18 mRNA transcript expression in VIN and 
iVSCC samples 
 
3.5.1 Expression of HPV 16 and HPV 18 mRNA transcripts  
The expression of HPV mRNA transcripts was analyzed by amplification of the E7 genes for 
HPV 16 and HPV 18 using qPCR. Results showed that mRNA expression of HPV 16 was 
obtained in 67.2 % of VIN and 50.0 % of iVSCC samples while positive HPV 18 mRNA 
expression was seen for 1.6 % of VIN and 6.1 % of iVSCC samples (Table 3.9). Results for 
DNA detection and mRNA transcript expression were compared (Table 3.9). Overall, HPV 
infection could be detected in 72.1 % and 68.9 % of VIN DNA and RNA samples, respectively 
while 65.2 % of DNA and 56.1 % of RNA extracted from iVSCC samples had HPV infection 
(Table 3.9). When comparing HPV 16 DNA detection and mRNA expression in VIN samples, 
it was found that DNA was identified in 68.9 % of samples compared to 67.2 % of samples 
where mRNA transcripts were expressed (Table 3.9). A slightly greater difference was 
observed between the detection of HPV 16 DNA and mRNA transcripts in iVSCC samples. 
HPV 16 DNA was amplified in 59.1 % of DNA and 50 % of RNA samples. For HPV 18, 
amplification was possible in 3.3 % of DNA and 1.6 % of RNA VIN samples while 10.6 % of 
iVSCC DNA and 6.1 % of iVSCC RNA samples were positive for HPV 18 (Table 3.9). 
Discordance between HPV DNA detection and mRNA HPV expression occurred in some 
samples such as VIN-040 and VIN-097 for which HPV 16 DNA was amplified but no mRNA 
transcripts were found.  HPV 16 DNA was detected in 6 iVSCC samples for which HPV 16 
mRNA transcripts were not detected (Table 3.9).  HPV 18 DNA could also be detected in one 
VIN and three iVSCC samples for which no mRNA transcripts could be amplified. 
Contrastingly, HPV 16 mRNA transcripts were found in VIN-044, a LSIL sample, but the 
DNA was undetectable. With regards to samples where mRNA transcripts could not be 
detected, plausible reasons might be similar to those states in Section 3.4.1. Additional to these 
reasons could be the HPV infections were not transcriptionally active.  
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Table 3.9: Comparison of HPV amplification in DNA and RNA VIN and iVSCC samples. 
 DNA RNA 
  HPV 16 HPV 18 HPV infection HPV 16 HPV 18 
HPV 
infection 
VIN (n=61) 42 (68,9 %) 2 (3,3 %) 44 (72,1 %) 41 (67,2 %) 1 (1,6 %) 42 (68,9 %) 
iVSCC (n=66) 39 (59,1 %) 7 (10,6 %) 43 (65,2 %) 33 (50 %) 4 (6,1 %) 37 (56,1 %) 
 
3.5.2 Sensitivity and specificity of HPV detection in DNA and RNA 
The sensitivity and specificity for the detection of HPV DNA and mRNA transcripts were 
compared for HPV 16 and 18 using EpiCalc 2000 (Version 1.02, Gilman and Matt, 1998). 
DNA amplification were used as the gold standard as the majority of HPV genotyping kits 
commercially available, are directed at DNA detection. The detection of HPV 16 mRNA in 
VIN samples (Table 3.10) had a sensitivity of 98 % (95 % confidence intervals (CI): 86 % – 
100 %) and a specificity of 90 % (95 % CI: 67 % – 98 %) while that of iVSCC samples (Table 
3.11) were 100 % (95 % CI: 87 % – 100 %) and 82 % (95 % CI: 64 % – 92 %), respectively.  
 
Table 3.10 Concordance and discordance of HPV 16 DNA and mRNA transcripts in VIN 
samples. 
    HPV DNA detection (GS)   
    Positive Negative Total 
mRNA HPV 
expression 
Positive 40 1 41 
Negative 2 18 20 
  Total 42 19 61 
 
 
Table 3.11 Concordance and discordance of HPV 16 DNA and mRNA transcripts in 
iVSCC samples. 
    HPV DNA detection (GS)   
    Positive Negative Total 
mRNA HPV 
expression 
Positive 33 0 33 
Negative 6 27 33 
  Total 39 27 66 
 
The sensitivity and specificity for the detection of HPV 18 mRNA transcripts in VIN samples 
(Table3.12) were 100 % (95 % CI: 50 – 89 %) and 98 % (95 % CI: 90 – 100 %), respectively, 
while the sensitivity and specificity for iVSCC samples (Table 3.13) were 100 % (95% CI: 40 
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– 98 %) and 95 % (95 % CI: 86 – 99 %). These findings suggest that using qPCR to test for the 
expression of HPV 16 and HPV 18 mRNA transcripts is precise and may be used to distinguish 
between the proportions of true positive as well as negative results with high accuracy.  
Furthermore, both the positive and negative predictive values for all comparisons were >80 %, 
suggesting a high probability for the positive and negative HPV 16 an HPV 18 mRNA 
expression results to be true. 
 
Table 3.12 Concordance and discordance of HPV 18 DNA and mRNA transcript detection 
in VIN samples. 
    HPV DNA detection (GS)   
    Positive Negative Total 
mRNA HPV 
expression 
Positive 1 0 1 
Negative 1 59 60 
  Total 2 59 61 
 
Table 3.13 Concordance and discordance of HPV 18 DNA and mRNA transcripts in 
iVSCC samples. 
    HPV DNA detection (GS)   
    Positive Negative Total 
mRNA HPV 
expression 
Positive 4 0 4 
Negative 3 59 62 
  Total 7 59 66 
 
 
3.6 Correlation of HPV DNA detection, koilocytosis and p16INK4a IHC staining of 
full section slides 
 
The use of p16INK4a IHC as a surrogate marker for HR-HPV infection is widely researched in 
anogenital malignancies and is commonly used in diagnostic settings as an ancillary test. 
However, the correlation of the presence of HPV with the overexpression of this biomarker in 
vulvar cancer is contentious (Sznurkowski et al., 2016). Some studies have reported high 
concordance of HPV and p16INK4a overexpression in vulvar carcinoma tissue while the opposite 
is also observed in other studies (Santos et al., 2006 as cited in Sznurkowski, Zawrocki and 
Biernat, 2016; De Sanjosé et al., 2013). Currently, there are no routine HPV test available at 
Tygerberg Academic Hospital and a positive HPV diagnosis is mainly reliant on the 
Stellenbosch University https://scholar.sun.ac.za
42 
 
 
observation of HPV-induced cellular changes using cytology and histology (Figure 3.4 and 
3.5). Therefore, the results based on the presence of these HPV cellular changes were used as 
gold standard in the following comparative analysis. 
 
 
 
 
 
 
 
 
 
 
The expression of p16INK4a in iVSCC samples with adequate FFPE tissue and the presence or 
absence of HPV-related cellular and structural changes in the tissue, together with the detection 
of HPV DNA were evaluated and compared. A total of 54 iVSCC were found to have adequate 
remaining tissue for IHC analysis (and subsequent TMA construction). The scoring of the 
p16INK4a IHC staining was blinded and done by a pathologist. Tissue were scored positive for 
p16INK4a IHC staining if block positivity (Figure 3.6) were observed and all other staining 
patterns were scored as negative (Figure 3.7), in line with the standard operating procedure for 
the scoring of routine diagnostic specimens. During the histological validation process, cellular 
changes caused by HPV known as koilocytosis were reported for 37.0 % (20/54) of the selected 
iVSCC samples. Overall, p16INK4a were positive in 77.8 % (42/54) of samples while HPV DNA 
could be detected in 63.0 % (34/54) of iVSCC samples.  
Figure 3.4 This figure illustrates HPV- induced 
cellular changes known as koilocytes (indicated 
by arrows) in a LSIL sample (VIN-002). 
Figure 3.5 This figure illustrates HPV-induced 
cellular changes known as koilocytes (indicated 
by arrows) in an HSIL sample (VIN-001). 
x 100 magnification 
x 100 magnification 
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When HPV DNA presence was compared with the observation of koilocytes, 24 % (13/54) of 
samples had both HPV DNA and koilocytic changes, whereas 39 % (21/54) were positive of 
the HPV DNA only. Koilocytes were observed in 13% (7/54) of cases in which HPV DNA 
could not be detected (Table 3.14). The presence of HPV DNA in the absence of cellular HPV-
related koilocytes changes may be due to the integration of HPV into the human genome, and 
may thus not be visible in iVSCC tissue.  Koilocytic atypia is usually an indicator for low grade 
lesions and LR HPV, and as demonstrated in this study its utility as a HPV indicator in invasive 
disease is poor.  
 
Figure 3.6 An example of iVSCC tissue sample (VSCC-033) stained with H&E (A) and  p16INK4a 
(B) to illustrate the block positive expression of p16INK4a. 
x 20 magnification x 20 magnification 
A B 
Figure 3.7 An example of iVSCC tissue sample (VSCC-048) stained with H&E (A) and p16INK4a (B) to 
illustrate a p16INK4a IHC negative result. 
 
x 20 magnification x 20 magnification 
A B 
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Table 3.14 Comparison of HPV presence in iVSCC samples based on koilocytosis and 
HPV DNA detection. 
    Koilocytic changes   
    Positive Negative Total 
HPV DNA 
detection 
Positive 13 21 34 
Negative 7 13 20 
  Total 20 34 54 
 
 
 
3.7 TMA construction of iVSCC tissue 
 
3.7.1 The evaluation of TMA quality using H&E staining 
A total of 54 iVSCC cases with adequate block thickness were identified for inclusion in the 
construction of the tissue microarray. IHC staining using antibodies against p16INK4a was 
performed on the full sections of these 54 tissue blocks in order to identify p16INK4a block 
positive cases, defined as strong nuclear and cytoplasmic expression in a continuous segment 
of cells. Of these, only 17 HIV negative and 25 HIV positive cases were diagnosed as p16INK4a 
block positive and were thus included in the TMA.  Two separate TMA’s were made for HIV 
positive and HIV negative samples.   
 
Sections from each TMA were evaluated for tumour and core presence using H&E staining. A 
total of 22/25 full cores were present on the HIV positive TMA, while there were partial cores 
for 3 of the 25 cores. All tissue cores except for one partially present core were visible on the 
HIV negative TMA. Capturing only a proportion of a tissue core on a slide may be due to lack 
of depth during sectioning of the TMA block or part of the tissue being lost during the staining 
procedure. The presence of tumour in the TMA FFPE core was an indication of the accurate 
marking and sampling of the tumour region on the full section slide and FFPE tissue block. For 
the HIV positive TMA, tumour were present for 22/25 cores while an absence of tumour tissue 
were reported for 3/25 cores. Only 1/17 cores present on the HIV negative TMA lacked tissue 
representative of iVSCC. These results may be due to human error as incorrect sampling or 
marking of the tumour area may occur. As the tissue sections expand during the capturing of 
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the tissue on the glass slide, it is sometimes difficult to effectively compare the marked H&E 
slide to the FFPE tissue block which may also lead to incorrect sampling of tissue cores. 
 
3.7.2 p16INK4a IHC staining on full section vs TMA slides  
As deeper sections into the TMA block were cut for IHC staining, tissue core presence was re-
evaluated for the IHC slides. A similar tissue core presence was observed in the H&E and IHC 
TMA slides with a total of 22/25 full cores, 2/25 partial cores and 1/25 absent core reported on 
the HIV positive IHC TMA while 16/17 full cores and 1/17 partial cores were observed in the 
HIV negative TMA.  As the tissue cores are derived from different FFPE blocks, the amount 
of tissue in each core differs from one another. Therefore, it is possible for some tissue cores 
to become depleted before others, hence the missing TMA core. A mentioned previously, the 
absence or partial absence of tissue cores may also be attributed to the H&E or IHC staining 
procedure as the tissue cores are small an may be easily removed during the numerous wash 
steps. As the partial cores were sufficient for the pathologist to interpret the IHC staining of 
the TMA, these samples were included in the comparative analysis while the absent core on 
the TMA of the tissue from HIV negative patients was excluded. Comparison of the p16INK4a 
staining pattern for full sections versus TMA cores were done collectively, for both HIV 
positive and HIV negative samples. As previously stated, tissue cores were only sampled from 
tissue with a block positive p16INK4a result on full section slides. An example of a TMA core 
sampled from VSCC-036 and stained with H&E and p16INK4a is illustrated in figure 3.8 A and 
B.  
 
 
 
 
  
 
 
 
 
 
 
Figure 3.8 An example of a TMA core from sample VSCC-036 stained with H&E (A) and p16INK4a (B). 
x 100 magnification x 100 magnification 
A B 
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Results showed 39/41 TMA cores were p16INK4a block positive while 2/41 TMA cores had a 
negative p16INK4a IHC stain result. A high sensitivity of 95 % (95 % CI:82 – 99 %) were 
achieved for the use of TMA cores for p16INK4a IHC staining of iVSCC tissue, indicating that 
there is good agreement between the positive scoring on full tissue sections and TMA sections. 
However, this finding indicates that TMA’s may be sufficient for biomarker studies that do not 
depend on the interpretation of the staining pattern such as p16INK4a but rather is reliant on 
scoring of absence or presence or intensity. A drawback of the TMA technique is that cores 
representative of tumour (and normal) tissue are identified using H&E stained slides and for 
p16INK4a stain assessment, the staining pattern of the entire excised lesion is normally evaluated. 
Therefore, if only a representative tissue core is taken, then the p16INK4a stain cannot be 
accurately analysed. A possible solution for this issue could be to take several cores 
representative of different histological regions. TMA’s could thus be used in ancillary testing 
of vulvar specimens (even additional to p16INK4a) or in the testing of new biomarkers for 
iVSCC, but care should be taken to sample representative tumour tissue.  
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Chapter 4    Conclusion 
 
The aim of the present study was to identify the prevalent HPV strains in vulvar pre-cancer and 
invasive iVSCC samples that were diagnosed at Tygerberg Academic Hospital between 
January1997 and June 2018. Only samples stored from January 2003 to June 2018 could be 
included in the study as, of the approximate 2500 listed samples obtained from clinical lists as 
well as data from the NHLS central data warehouse, only 312 were deemed suitable.  The age 
at which the majority of the patients were diagnosed were analysed and compared to the 
detection of HPV DNA plus known risk factors such as HIV infection. The distribution of the 
detected HPV subtypes among the different histological subgroups were also investigated and 
compared. Furthermore, the sensitivity and specificity of the different methods used to 
investigate the presence of HPV such as qPCR to amplify DNA and mRNA transcript 
expression as well as p16INK4a IHC were evaluated. Lastly, we investigated whether TMAs were 
suitable for the purpose of biomarker expression analysis in vulvar cancer tissue.  
 
It was found that HPV 16 was the most prevalent strain detected among VIN and iVSCC 
samples included in this study. However, further studies are needed to confirm these results 
and to be able to extend the findings to the broader community. Contrary to what is reported in 
other African countries, HPV 35 was the least frequent strain detected in our study population, 
suggesting that the prevalence of HPV subtypes may vary in different geographical regions 
(Akarolo-Anthony et al., 2014). However, a comparative study with larger sample numbers 
from a variety of different African regions is needed to confirm such observations. A positive 
correlation between HPV infection, diagnoses of VIN and iVSCC and HIV seropositivity was 
noted.  However, statistical tests revealed no significant difference between HIV positive and 
HIV negative in either VIN or iVSCC samples for which HPV DNA was detected.  As the 
majority of samples, regardless of diagnosis, for which multiple HPV infections were detected 
had an HIV co-infection, it could be  concluded that, in our sample study, HIV infection may 
increase the risk of being infected with multiple HPV strains or vice versa that HPV infection 
may increase the risk of contracting HIV, which is in concordance with available literature 
(Giuliano, Botha, Zeier, Abrahamsen, Glashoff, van der Laan, Papenfuss, Engelbrecht, Schim 
van der Loeff, Sudenga, Torres, Kipping & Taylor, 2015; Williamson, 2015). 
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VIN and iVSCC was found to be diagnosed in a substantially younger population, with the 
majority of diagnoses made for patients younger than 59 years old. This study thus supports 
the findings from a previous study done at Tygerberg Academic Hospital (Butt and Botha, 
2017), which found that vulva carcinoma was not a disease of the elderly in our setting but 
rather occurred at a much younger age. A significant relationship was also observed between 
HIV status and patient age, as the majority of patients in the younger age groups (younger than 
59) were HIV positive while women in the older age groups were predominantly HIV negative. 
However, due to the small sample size and the rarity of the disease, more studies are needed to 
confirm this finding. It is therefore concluded that HIV status may play a role in younger 
patients developing vulva cancer as immunosuppression is known to increase susceptibility to 
HPV infection and may accelerate the progression of this disease.   
 
Upon assessing the presence of HPV in different VIN and iVSCC histological subgroups, it 
was found that the majority of samples in which HPV was detected were classified as HSIL 
(VIN II/III), keratinizing and non-keratinizing histological groups. According to the WHO 
Classification of Tumours of the Female Reproductive Organs, keratinizing carcinomas are 
often HPV independent and p16INK4a negative with the presence of dVIN in adjacent epithelium 
(Kurman et al., 2014). Current literature frequently concludes higher HPV detection in warty 
and basaloid iVSCC subgroups, with only a small percentage of keratinizing variants which 
are not normally associated with HPV (Faber et al., 2017; Madeleine et al., 1997; Pils, 
Gensthaler, Alemany, Horvat, de Sanjosé & Joura, 2017). However, the majority of iVSCC 
samples included in this study were classified as keratinizing and non-keratinizing compared 
to substantially lower amounts of warty and basaloid iVSCC subgroups observed.  
 
When HPV 16 and HPV18 mRNA expression were compared to DNA detection, a high 
concordance was established between the two techniques. Therefore, detection of mRNA 
transcripts using qPCR is highly sensitive and may produce high accuracy of true positive and 
negative HPV results. Likewise, high concordance was found for p16INK4a expression analysed 
with IHC when the staining of full section slides was compared to that of the TMA slides, 
bearing in mind that only p16INK4a block positive sample were used. However, in the case of 
the vulvar, TMA’s may be more useful for additional testing of samples to p16INK4a. TMA’s 
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may also be suitable for testing of novel biomarkers for iVSCC for which the scoring is more 
reliant on the presence or absence of the biomarker rather than staining pattern. 
 
A major limitation of this study was the inaccessibility of FFPE tissue blocks either for the 
samples from January 1997 to December 2002 as well as those which could not be retrieved. 
Another drawback experienced in this study is the large number of VIN cases for which HIV 
status was unknown and which could therefore not be included in the HIV-related analyses. As 
previously stated, due to the low sample size, results cannot be extrapolated to the wider 
population. Similar ancillary studies in different regions of the Western Cape and South Africa 
is recommended to determine if HPV 16 is the most prevalent strain in HPV dependent vulvar 
neoplastic disease. This knowledge will confirm whether the current bivalent HPV vaccine 
(against HPV subtypes 16 and 18) used in government-operated healthcare facilities will 
suffice to cover HPV driven vulvar disease, in addition to cervical pathology. The effect of 
national HPV vaccination will only be evident in the following decades. In the meantime, many 
vaccination naïve women will only present late with a palpable vulvar lesion, as screening tests 
for vulvar neoplasms are lacking. Future perspective studies allude to the development of a 
vaccine that could also have a therapeutic role. Awareness of the prevalent HPV strains for 
vulvar neoplasia is therefore needed in our setting. More so, once pre-neoplastic disease is 
already established, the clinical task of constant surveillance, discerning invasive lesions from 
precursor lesions and deciding on the extent of surgery is challenging and cumbersome. 
Removing precursor lesions do not always guarantee against invasive disease development. 
The disfiguring surgery also has far reaching effects on patients’ psychosocial being. Until the 
benefits of HPV vaccination are seen, a large population of unvaccinated woman is still prone 
to vulvar disease. The search for new biomarkers, anti-tumour agents and predictors for disease 
outcome, especially to predict progression from precursor lesions to invasive disease is still 
much needed. 
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